Nucleic acid sequences from drosophila melanogaster that encode proteins essential for viability and uses thereof

Abstract
Nucleotide sequences are isolated from Drosophila melanogaster that code for proteins essential for viability. These proteins are useful for discovering new insecticides based on the essentiality of the nucleotide sequences for Drosophila viability. Further provided are recombinant proteins and methods for identifying inhibitors to these proteins. Protein inhibitors active in the methods disclosed herein are useful as insecticidal, ectoparasiticidal, antiparasitic, anthementhic and acaracidal agents.
Description

The Sequence Listing associated with the instant disclosure has been submitted as a 2.62 megabyte file on CD-R (in duplicate) instead of on paper. Each CD-R is marked in indelible ink to identify the Applicants, Title, File Name (70131WOPCT.ST25.txt), Creation Date (Aug. 7, 2003), Computer System (IBM-PC/MS-DOS/MS-Windows), and Docket No. (70131 WOPCT). The Sequence Listing submitted on CD-R is hereby incorporated by reference into the instant disclosure.


FIELD OF INVENTION

The present invention pertains to nucleic acid sequences isolated from Drosophila melanogaster that encode proteins essential for viability. The invention particularly relates to methods of using these proteins as insecticide targets, based on this essentiality.


BACKGROUND OF THE INVENTION

Insects contribute or cause many human and animal diseases, and are responsible for substantial agricultural and property damage. The societal costs associated with insect pests in dollars, time and suffering are monumental. The total worldwide market size for insecticide crop protection is over $5 billion. To combat these problems, insecticidal compounds have been developed and employed.


The idea to use chemicals for insect control is not new. The scientific use of pesticides started with the introduction of arsenical insecticides and organic compounds such as tar, petroleum oils, and dinitrophenol emulsions at the end of the last century. But, the systematic search for synthetic organic insecticides was only launched after the discovery of the insecticidal properties of DDT in 1939. After World War II, chemical research concentrated mainly on chlorinated hydrocarbons and cyclodienes, which all require high rates of application and have a rather broad spectrum of activity. Most of them are persistent in the environment and may pose a significant risk for accumulation in the food chain. Today the use of these chemicals is very much restricted.


From this point, the major emphasis in research has been given to organophosphates and carbamates, which are readily degradable in the environment with little tendency for bioaccumulation. The toxicity of these compounds varies within a broad range from medium to highly toxic. Organophosphates and carbamates are still widely use, although the more toxic ones are banned in certain countries. The formamidines have as their major advantage a different mode of action and their selectivity, which made them suitable for use in IPM (insect pest management) programs. They are easily degradable with no accumulation potential, but for toxicological reasons some have had to be withdrawn from the market.


For the past decade, insecticide research has concentrated on leadfinding for new chemical structures interfering with new target mechanisms. The chances for success are rather remote, because the hurdles for the registration of a new insecticide are set very high. Toxicological aspects, insecticide resistance, environmental behavior, and IPM fitness are some of the critical factors that have to be considered together with economical factors.


Novel insecticides can now be discovered using high-throughput screens that implement recombinant DNA technology. Proteins found to be essential to insect viability can be recombinantly produced through standard molecular biological techniques and utilized as insecticide targets in screens for novel inhibitors of the enzymes' activity. The novel inhibitors discovered through such screens may then be used as insecticides to control undesirable insect infestation.


However, as the world population continues to grow, there will be increasing food shortages. Therefore, there exists continuing need to find new, effective and economic insecticides.


SUMMARY OF THE INVENTION

In view of these needs, it is one object of the invention to provide essential genes in insects such as Drosophila melanogaster. It is another object to provide the essential proteins encoded by these essential genes for assay development to identity inhibitory compounds with insecticidal activity. It is still another object of the present invention to provide an effective and beneficial method for identifying new or improved insecticides using the essential proteins of the invention.


In furtherance of these and other objects, the present invention provides DNA molecules comprising nucleotide sequences isolated from Drosophila melanogaster that encode proteins essential for viability. The inventors are the first to demonstrate that the nucleotide sequences of the invention are essential for viability. This knowledge is exploited to provide novel insecticide modes of action. One advantage of the present invention is that the proteins encoded by the essential nucleotide sequences provide the bases for assays designed to easily and rapidly identify novel insecticides.


Disruption of the nucleotide sequences or messenger RNA of the invention demonstrates that the activity of each corresponding encoded protein is essential for Drosophila viability. Genetic results show that when each nucleotide sequence of the invention is mutated in Drosophila or disrupted at the transcription level, the resulting phenotype is lethal. This demonstrates a critical role for the protein encoded by the mutated nucleotide sequence. This further implies that chemicals that inhibit the expression of the protein when in contact with insects are likely to have detrimental effects on insects and are potentially good insecticide candidates. The present invention therefore provides methods of using the disclosed nucleotide sequences or proteins encoded thereby to identify inhibitors thereof. The inhibitors can then be used as insecticides to kill undesirable insect populations where crops are grown, particularly agronomically important crops such as maize, and other cereal crops such as wheat, oats, rye, sorgum, rice, barley, millet, turf and forage grasses and the like, as well as cotton, sugar cane, sugar beet, oilseed rape, soybeans, vegetable crops and fruits.


The present invention accordingly provides cDNA sequences derived from Drosophila melanogaster. In one embodiment, the present invention provides an isolated DNA molecule comprising a nucleotide sequence selected from the group consisting of the even numbered SEQ ID NOs:14-380. In another embodiment, the present invention provides an isolated DNA molecule comprising a nucleotide sequence that encodes a protein selected from the group consisting of the odd numbered SEQ ID NOs:15-381.


The present invention also provides a chimeric construct comprising a promoter operatively linked to a DNA molecule according to the present invention, wherein the promoter is preferably functional in a eukaryote, wherein the promoter is preferably heterologous to the DNA molecule. The present invention further provides a recombinant vector comprising a chimeric construct according to the present invention, wherein said vector is capable of being stably transformed into a host cell. The present invention still further provides a host cell comprising a DNA molecule according to the present invention, wherein said DNA molecule is preferably expressible in the cell. The host cell is preferably selected from the group consisting of an insect cell, a yeast cell, and a prokaryotic cell.


The present invention also provides proteins essential for Drosophila melanogaster viability. In one embodiment, the present invention provides an isolated protein comprising an amino acid sequence selected from the group consisting of the odd numbered SEQ ID NOs:15-361. In accordance with another embodiment, the present invention also relates to the recombinant production of proteins of the invention and methods of using the proteins of the invention in assays for identifying compounds that interact with the protein.


In another preferred embodiment, the present invention describes a method for identifying chemicals having the ability to inhibit the activity of the disclosed proteins. In a preferred embodiment, the present invention provides a method for selecting compounds that interact with a protein of the invention, comprising: (a) expressing a DNA molecule according to the present invention to generate the corresponding protein of the invention, (b) testing a compound suspected of having the ability to interact with the protein expressed in step (a), and (c) selecting compounds that interact with the protein in step (b).


Other objects and advantages of the present invention will become apparent to those skilled in the art and from a study of the following description of the invention and non-limiting examples. The entire contents of all publications mentioned herein are hereby incorporated by reference.


BRIEF DESCRIPTION OF THE SEQUENCES IN THE SEQUENCE LISTING

SEQ ID NOs:1-13 are PCR primers.


Even numbered SEQ ID NOs:14-380 are nucleotide sequences described in the table below.


Odd numbered SEQ ID NOs:15-381 are protein sequences encoded by the immediately preceding nucleotide sequence, e.g., SEQ ID NO:15 is the protein encoded by the nucleotide sequence of SEQ ID NO:14, SEQ ID NO:17 is the protein encoded by the nucleotide sequence of SEQ ID NO:16, etc.

TABLE 1Drosophila SequencesseqInventor'sIDreferencefunctionDomainsBest blast hitscore14-15CT28483CG10260PI3Ka, PI3_4_KINASE_1,(D83538) 230 kDa1600EG: BACR7C10.2 proteinPI3_4_KINASE_2,phosphatidylinositol 4-kinasekinase, 1-PI3_4_KINASE_3,[Rattus norvegicus]phosphatidylinositol 4-PI3_PI4_kinasekinase16-17CT28925CG10365 unknownhypothetical protein MGC4504185[Homo sapiens]18-19CT29122CG10370 Tbp-1 Tat-AAA, ATP_GTP_A,Q63569|PRSA_RAT 26S720binding protein-1,MITOCH_CARRIERPROTEASE REGULATORYProteasome 26SSUBUNIT 6A (TAT-BINDINGregulatory subunit 6A,PROTEIN 1) (TBP-1)multicatalyticendopeptidase,20-21CT29492CG10545 Gb13F GGPROTEINB,GBB1_CAEEL GUANINE619protein b-subunit 13F, G-GPROTEINBRPT, WD40,NUCLEOTIDE-BINDINGprotein coupled receptor,WD40_REGION,PROTEIN BETA SUBUNIT 1protein signaling pathwayWD_REPEATS22-23CT30008CG10701 Moe Dmoesin,BAND41, BAND_41_1,Homo sapiens ‘moesin’motor involved inBAND_41_2, BAND_41_3,gi: 4505257cytoskeleton organizationBand_41, ERM, ERMFAMILYand biogenesis24-25CT30208CG10776 witPROTEIN_KINASE_ATP,NP_031587.1| (NM_007561)362Serine/threonine kinase-PROTEIN_KINASE_DOM,bone morphogenic proteinD; wishful thinking, a typeTGFB_RECEPTOR, pkinasereceptor, type IIII transforming growthfactor beta receptorinvolved in proteinphosphorylation26-27CT30807CG10997 chlorideNP_001280.2| (NM_001289)119channel?chloride intracellular channel 2[Homo sapiens]28-29CT30887CG11033 unknownNP_036440.1| (NM_012308) F-431box and leucine-rich repeatprotein 1130-31CT31117CG11130 Rtc1 RNA 3′Q9Y2P8|RCL1_HUMAN RNA326terminal phosphate3′-TERMINAL PHOSPHATEcyclase, Rtc1CYCLASE-LIKE PROTEIN(HSPC338)32-33CT1249CG1114 Weak similarityNP_071334.1| (NM_022051)249with apoptosis protein RP-egl nine homolog 1 (C. elegans)8,34-35CT1483CG1119 Gnf1 Germ lineATP_GTP_A, BRCT,A49651 replication factor C661transcription factor 1,BRCT_DOMAIN, NLS_BP,large subunit - humanDNA binding/DNARFCreplication factor36-37CT7860CG11190 unknownBAB60854.1| (AB057724)387phosphatidyl inositol glycanclass T [Homo sapiens]38-39CT1834CG1135 unknownFHA, FHA_DOMAINNP_006328.1| (NM_006337)383microspherule protein 1; cellcycle-regulated factor40-41CT31875CG11418 EG: 8D8.8NP_060579.1| (NM_018109)252involved in cell cyclehypothetical protein FLJ10486[Homo sapiens]42-43CT36241CG11452 unknownnone44-45CT1993CG1149 MstProxLRRNTHomo sapiens ‘toll-likeMstProx, transmembranereceptor1’ gi: 4507527receptor involved indefense response46-47CT34608CG11511 similarity toZINC_FINGER_C2H2,AAC78286.1| (AF032674)128broad-complex Z2-ZINC_FINGER_C2H2_2, zf-broad-complex Z2-isoformisoformC2H2[Manduca sexta]48-49CT5404CG11595 unknownnone50-51CT17728CG11779 receptor -XP_049282.1| (XM_049282)436mitochondrialtranslocase of innertransporter???mitochondrial membrane 44homolog52-53CT1465CG12007NP_004572.1| (NM_004581)278geranylgeranyltransferase,Rab geranylgeranyltransferase,alpha subunitalpha subunit [Homo sapiens]54-55CT5438CG12079 NADHcomplex1_30 KdAAD40386.1| (AF100743)323dehydrogenaseNADH-Ubiquinone reductase(ubiquinone)[Homo sapiens]56-57CT43008CG12085 pUbsf DPUF68RBD, RNP_1, rrmNP_525123.1| (NM_080384)1037Puf60 polyU bindingpoly-U-binding splicing factorsplicing factor, poly(U)binding involved inmRNA splicing58-59CT5902CG12093 unknownCRYSTALLIN_BETAGAMMANP_499515.1| (NM_067114)137Y41C4A.8.p [Caenorhabditiselegans]60-61CT6734CG12113 unknownATP_GTP_AAAH08013 (BC008013) Similar498to CG12113 gene product[Homo sapiens]62-63CT7760CG12135 c12.1 unknownAF110775_1 (AF110775)252adrenal gland protein AD-002[Homo sapiens]64-65CT9355CG12181 Sgs4 sgs-4Mus musculus Sap62salivary gland secretionMGI: 104912protein 4, pupal glueprotein66-67CT12665CG12225 Spt6 spt6,S1Caenorhabditis eleganspromoter-associatedT04A8.14 WP: CE13120pausing andtranscriptional elongation68-69CT13424CG12238 'probableNP_060758.1| (NM_018288)222transcription factorhypothetical protein FLJ10975[Homo sapiens]70-71CT14932CG12251 AQP AQPXP_059490.1| (XM_059490)62.4aquaporin, water channelhypothetical protein XP_059490[Homo sapiens]72-73CT23511CG12348 Sh openrectifying potassiumchannel, shaker74-75CT32757CG12482 unknownNP_076113.1| (NM_023624)40.8lecithin-retinol acyltransferase[Mus musculus]76-77CT33237CG12497LDLRA_1, LDLRA_2,CAC86027.1| (AJ313389) tsetse90.9EG: BACR25B3.2 low-LDLRECEPTOR, NLS_BP,EP protein [Glossina morsitansdensity lipoproteinPRO_RICH, ldl_recept_amorsitans]receptor-like78-79CT33996CG12537 unknownAAK31375.1|AC084329_1116(AC084329) ppg3 [Leishmaniamajor]80-81CT34671CG12600 unknownWW_rsp5_WWPAF213258_1 (AF213258)56.2membrane-associated guanylatekinase-related MAGI-3 [Mus musculus]82-83CT2591CG1265 unknownXP_059471.1| (XM_059471)67.8similar to MANNOSE-P-DOLICHOL UTILIZATIONDEFECT 184-85CT35764CG12701 unknownNLS_BP, PRO_RICH,NM_078717) kismet117ZINC_FINGER_C2H2,[Drosophila melanogaster]ZINC_FINGER_C2H2_2, zf-C2H286-87CT28931CG12750 nucampholin,RNA binding(AB046824) KIAA1604 protein833transcription factor?[Homo sapiens]88-89CT32253CG13034 unknown(AC084329) ppg3 [Leishmania94.4major]90-91CT32701CG13372 EG: 171D11.6noneunknown92-93CT40992CG13372 EG: 171D11.6noneunknown94-95CT32721CG13380 unknownNP_499428.1| (NM_067027)43.5W09D6.5.p [Caenorhabditiselegans]96-97CT33014CG13620 unknownCYTOCHROME_C, NLS_BP,Caenorhabditis elegans ‘similarZINC_FINGER_C2H2,to Zinc finger, C2H2 typeZINC_FINGER_C2H2_2, zf-C2H298-99CT33019CG13625 histoneNLS_BPNP_498982.1| (NM_066581)265protein?R08D7.1.p [Caenorhabditiselegans]100-101CT33241CG13760Cysteine proteinases(AK054681) unnamed protein144EG: BACR25B3.6product [Homo sapiens]unknown102-103CT33317CG13818 unknownATP_GTP_AT26047 hypothetical protein39.3W01C8.5 - Caenorhabditiselegans104-105CT3228CG1405 cg1405 ATPHELICASE, helicase_CXP_008088.1| (XM_008088)825dependent helicasepre-mRNA splicing factor Prp16[Homo sapiens]106-107CT33819CG14206 structuralAF400207_1 (AF400207)225protein of ribosomeribosomal protein S10[Spodoptera frugiperda]108-109CT3352CG1422 p115 vesicularP41541|VDP_BOVIN General725transporter, membranevesicular transport factor p115docking110-111CT33841CG14226 CT33841fn3NP_075214.1| (NM_022925)93.6protein tyrosineprotein tyrosine phosphatase,phosphatasereceptor type, Q [Rattus112-113CT34063CG14411 proteinCRYSTALLIN_BETAGAMMAAAK26171.1| (AY028703)211phosphatasephosphatidylinositol-3 phosphate3-phosphatase adaptor114-115CT3509CG1448 inx3 innexin 3Q9XYN1|INX2_SCHAM332Innexin Inx2 (Innexin-2) (G-Inx2)116-117CT34434CG14656 unknownNP_542443.1| (NM_080712)122tty-P1 [Drosophilamelanogaster]118-119CT34588CG14778 integral(AE003604) CG2022 gene179peroxisomal membraneproduct [Drosophila melanogaster]120-121CT43287CG14779 EG: 80H7.2Tubulin-beta mRNAnonetubulin-beta mRNAautoregulation signal domainautoregulation signalprotein122-123CT34589CG14779 EG: 80H7.2Tubulin-beta mRNAnonetubulin-beta mRNAautoregulation signal domainautoregulation signalprotein124-125CT34599CG14789AA_TRNA_LIGASE_IAF455270_1 (AF455270)261EG: BACN32G11.6C21ORF80 [Mus musculus]Aminoacyl-transfer RNAsynthetases class-Isignature protein126-127CT34602CG14792 sta Laminin-RIBOSOMALS2,(AB032438) stubarista410receptor Stubarista,RIBOSOMAL_S2_1,[Drosophila erecta]protein biosynthesis Rp40RIBOSOMAL_S2_2,Ribosomal_S2128-129CT34626CG14813 delta; COPATP_GTP_A: ATP/GTP-NP_001646.2| (NM_001655)585coatomer complex COPIbinding site motif A (P-loop)archain; coatomer protein delta-delta-COP subunit deltaproteinCOP [Homo sapiens]130-131CT34665CG14849 unknownnone132-133CT3729CG1489 Pros45 sug1,AAA, ATP_GTP_AP54814|PRS8_MANSE 26S727multicatalyticPROTEASE REGULATORYendopeptidase regulator,SUBUNIT 8 (18-56 PROTEIN)multicatalyticendopeptidase,,proteasome ATPase,preoteolysis andpepitolysis134-135CT34842CG14991 unknownBAND_41_3, PH_DOMAINXP_051693.1| (XM_051693)635mitogen inducible 2 [Homosapiens]136-137CT34979CG15104 topoisomeraseNP_055023.1| (NM_014208)102I-binding RS protein’dentin sialophosphoprotein;dentin phosphophoryn;138-139CT3955CG1530 unknownPRO_RICHXP_092523.1| (XM_092523)230hypothetical protein XP_092523[Homo sapiens]140-141CT35308CG15321 unknownnone142-143CT35676CG15560 putative cellNP_499205.1| (NM_066804)170membrane-associatedTransmembrane and sushimucindomain [Caenorhabditis elegans]144-145CT30180CG15811 Rop rop, ‘RasSec1NP_037170.1| (NM_013038)756oppositesyntaxin binding protein 1[Rattus norvegicus]146-147CT34113CG15896 unknownNP_055487.1| (NM_014672)182KIAA0391 gene product [Homosapiens]148-149CT34115CG15898 unknownNP_078828.1| (NM_024552)47.8hypothetical protein FLJ12089[Homo sapiens]150-151CT4708CG1683 Ant2 Ant2,ADPTRNSLCASE,(AF218587) ADP/ATP485ADP/ATP translocase.MITOCARRIER,translocase [Lucilia cuprina]Adenine nucleotideMITOCH_CARRIER, mito_carrtranslocase 2, ATP/ADPantiporter152-153CT37506CG16903 EG: 67A9.2NP_446114.1| (NM_053662)411non-specific RNAcyclin L [Rattus norvegicus]polymerase IItranscription factor154-155CT35131CG16916 Rpt3 p48A, 26SAAA, CLPPROTEASEAPRS6_MANSE 26S681proteasome regulatoryPROTEASE REGULATORYcomplex subunit p48ASUBUNIT 6B (ATPASE MS73)156-157CT4802CG1696 unknownNP_056158.1| (NM_015343)341hypothetical protein [Homosapiens]158-159CT43084CG1697 rho-4 rho-4 Rho-Rattus norvegicus ‘rhomboid-related [10C6] rhomboid-4related protein’EMBL: Y17258160-161CT4810CG1698 unknownnone162-163CT4826CG1703 ATP-bindingABC_TRANSPORTER,(AF293383) ABC50 [Rattus802cassette (ABC) transporterABC_tran, ATP_GTP_A,norvegicus]ATP_GTP_A2, DA_BOX,NLS_BP164-165CT35402CG17252 BCL7-like(NM_001707) B-cell94.4BCL7-likeCLL/lymphoma 7B [Homosapiens]166-167CT21145CG17309 CSK CSK,PROTEIN_KINASE_ATP,AAH18394 (BC018394) c-src462involved in proteinPROTEIN_KINASE_DOM,tyrosine kinase [Mus musculus]phosphorylationPROTEIN_KINASE_TYR,SH2, SH2DOMAIN,TYRKINASE, pkinase168-169CT5050CG1740 Ntf-2 NTF-2,NTF2_DOMAIN(NM_059921) nuclear transport127protein carrier involved infactor 2 like [Caenorhabditisprotein-nucleus import170-171CT5086CG1746 anon-ATP-synt_C, ATPASEC,Q9U505|ATPC_MANSE ATP177EST: Posey224 hydrogen-ATPASE_Csynthase subunit C,transporting ATPmitochondrial precursor (Lipid-synthase/enzyme,bindinghydrogen-transportingtwo-sector ATPase172-173CT34491CG17734 unknownNP_062788.1| (NM_019814)82.4hypoxia induced gene 1 [Musmusculus]174-175CT39345CG17766 EG: 86E4.3WD40, WD40_REGIONAF188123_1 (AF188123) TGF-1160heterotrimeric G-proteinbeta resistance-associatedGTPaseprotein TRAG [Mus musculus]176-177CT39414CG17791 sqdRBD, rrm; Eukaryotic putativeHomo sapiens ‘heterogeneousheterogeneous-nuclear-RNA-binding region RNP-1nuclear ribonucleoprotein D’ribonucleoprotein-87Fbsignature, RRM-motif protein,EMBL: AF026126RNA-binding protein 3,RRM-motif proteinSquid178-179CT39758CG17871 Or71a trachealnonegasfilling mutant1b,Or71a, odorant receptor180-181CT40282CG18009 Trf2 TATA box(AB024489) TBP-like protein210binding protein-related[Gallus gallus]factor 2182-183CT5456CG1826 productBTB, NLS_BP,(AB067467) KIAA1880 protein595involved in developmentalPROTEIN_SPLICING[Homo sapiens]processes184-185CT41472CG18282 Ubiquitin-likeI45964 polyubiquitin - bovine431(fragment)186-187CT42468CG18578 Ugt86Da UDP-noneglucuronosyltransferase188-189CT13908CG18734 Fur2 furinT43251 furin (EC 3.4.21.75) -1753fall armyworm190-191CT5890CG1908 unknownNLS_BPnone192-193CT5932CG1915 sls sallimus,AA_TRNA_LIGASE_II_1,Gallus gallus ‘connectin/titin’myosin light chain kinaseATP_GTP_A, NLS_BP, SH3,EMBL: D83390fn3, ig194-195CT6007CG1937 involved in cell(AF317634) HRD1 [Homo545growth and maintenancesapiens]196-197CT5951CG1938 Dlic2 Dlic2,ATP_GTP_A(AF317841) cytoplasmic dynein399motor which is alight-intermediate chain 1component of the[Xenopusmicrotubule associatedprotein198-199CT6352CG1994 similar toATP_GTP_A(AB051496) KIAA1709 protein1013Achlya ambisexualis[Homo sapiens]antheridiol steroidreceptor200-201CT6373CG2003 high affinitytransporterHomo sapiens ‘Na/PO4inorganiccotransporter’ gi: 4885441phosphate:sodiumsymporter202-203CT4336CG2151 Trxr-1 NOTFADPNR, HGRDTASE,(U88187) glutathione reductase753glutathione reductaseNAD_BINDING,family member [Musca(NADPH) (EC: 1.6.4.2)PNDRDTASEI,domestica]involved in thioredoxinPYRIDINE_REDOX_1,reductionpyr_redox203-205CT6738CG2165 BEST: CK01140(NM_053311) ATPase, Ca++1262calcium-transportingtransporting, plasma membraneATPase-like1 [Rattus206-207CT5965CG2184 Mlc2 muscle-EF_HAND, EF_HAND_2,MLR5_FELCA Superfast130specific myosin regulatoryefhandmyosin regulatory light chain 2light chain Mlc2, involved(MYLC2)in cell motility208-209CT7322CG2222 unknownnone210-211CT7705CG2309 ERK7 proteinYPC2_CAEEL Putative392kinase, proteinserine/threonine-protein kinaseserine/threonine kinaseC05D10.2 in chromosome III212-213CT8341CG2520 lap lap,ENTH(AF182339) clathrin assembly502chaperoneprotein AP180 [Loligo pealei]214-215CT9021CG2666 CS-1 CS-1,(AF221067) chitin synthase 12770enzyme/chitin synthase[Lucilia cuprina]216-217CT9593CG2829NLS_BP, PFKB_KINASES_1,(AB004884) PKU-alpha [Homo520BcDNA: GH07910 proteinPROTEIN_KINASE_ATP,sapiens]kinase, proteinPROTEIN_KINASE_DOM,serine/threonine kinasePROTEIN_KINASE_ST,PRO_RICH, pkinase218-219CT9754CG2849 Rala Ral, RASATP_GTP_A, PRENYLATION,(XM_035787) similar to Ras-304small monomeric GTPase,RASTRNSFRMNG, rasrelated protein RAL-A [Homoregulates developmentalsapiens]cell shape changesthrough the JNK pathway220-221CT9660CG2829NLS_BP, PFKB_KINASES_1,(AB004884) PKU-alpha [Homo520BcDNA: GH07910 proteinPROTEIN_KINASE_ATP,sapiens]kinase, proteinPROTEIN_KINASE_DOM,serine/threonine kinasePROTEIN_KINASE_ST,PRO_RICH, pkinase222-223CT6171CG2968 hydrogen-P35434|ATPD_RAT ATP142transporting ATPsynthase delta chain,synthase, coupling factormitochondrial precursorCF(0), delta-chain224-225CT10206CG3034 EG: BACR7A4.6(Y15172) surfeit protein 5183similar to Surf5b [Homo[Takifugu rubripes]sapiens226-227CT41361CG3071 EG: 25E8.3Trp-Asp (WD) repeats signatureT40471 probable Trp-Asp repeat273involved in retrogradeproteinprotein - fission yeast(Golgi to ER) transportwhich is putatively acomponent of thecoatomer228-229CT9947CG3071 EG: 25E8.3Trp-Asp (WD) repeats signatureT40471 probable Trp-Asp repeat273involved in retrogradeproteinprotein - fission yeast(Golgi to ER) transportwhich is putatively acomponent of thecoatomer230-231CT10723CG3201 Mlc-c Mlc-c,EF_HAND, EF_HAND_2,Homo sapiens ‘MYOSINalkali light chain of non-efhandLIGHT CHAIN ALKALI,muscle myosin-II,SMOOTH-MUSCLEcytoskeleton organizationISOFORM (MLC3SM)and biogenesis(LC17B) (LC’ SWP: P24572232-233CT11063CG3313 transcriptionNLS_BP, WD40,(AB067479) KIAA1892 protein293factorWD40_REGION[Homo sapiens]234-235CT11487CG3415 estradiol 17ADH_SHORT, GDHRDH,(NM_000414) hydroxysteroid613beta-dehydrogenaseTHIOL_PROTEASE_HIS,(17-beta) dehydrogenase 4adh_short[Homo sapiens]236-237CT11597CG3446 unknown(AJ316011) mitochondrial78.6NADH: ubiquinoneoxidoreductase B16.6238-239CT11623CG3455 Rpt4 Rpt4,Manduca sex ‘26S proteasomeendopeptidase,regulatory ATPase subunit 10bmulticatalytic(S10b)’ EMBL: AJ223384endopeptidase regulator,multicatalyticendopeptidase,proteasome ATPase240-241CT11966CG3560 anon-1BCC|F Chain F, Cytochrome150EST: Posey167 NADHBc1 Complex From Chickendehydrogenase242-243CT12417CG3703(NM_075735) T19D7.4.p251EG: BACR7A4.15[Caenorhabditis elegans]cytoskeleton organizationand biogenesis244-245CT12443CG3715 Shc dShc, SHC-S25776 transforming protein267adaptor protein, protein(SHC) - humankinase putatively involvedin cell growth andmaintenance246-247CT12517CG3747 Eaat1 Eaat1,plasma membrane(AF330257) glutamate402glutamate transporter,transporter [Mus musculus]Excitatory amino acidtransporter 1248-249CT12871CG3861 citrate (SI)-CITRATE_SYNTHASE,P00889|CISY_PIG CITRATE674synthaseCITRTSNTHASE, citrate_syntSYNTHASE,MITOCHONDRIALPRECURSOR250-251CT12909CG3874 nucleotide-sugar(NM_015139) UDP-glucuronic361transporter-likeacid/UDP-N-acetylgalactosamine dual252-253CT13223CG3981 Unc-76 Dunc-(NM_005102) zygin 2;19776, signal transducerfasciculation and elongationinvolved in axon cargoprotein zeta 2;transport254-255CT4722CG4013 Smr SmrterANTIFREEZEI, myb_DNA-NCR2_MOUSE NUCLEAR275SMRT-related ecdysonebindingRECEPTOR CO-REPRESSORreceptor-interacting factor2 (N-COR2) (SILENCINGSANT domain protein,MEDIATOR OFtranscription corepressor256-257CT13458CG4094 fumarateDCRYSTALLIN,(NM_017005) fumarate512hydratase, enzymeFUMARATE_LYASES,hydratase [Rattus norvegicus]involved in mainFUMRATELYASE, lyase_1pathways of carbohydratemetabolism258-259CT13690CG4129(XM_043094) KIAA0061325BcDNA: LD21623protein [Homo sapiens]unknown260-261CT5938CG4147 Hsc70-3 Hsc70-ER_TARGET,(AB016836) heat shock 70 kD11593, Heat shock proteinHEATSHOCK70, HSP70,protein cognate [Bombyx mori]cognate 3, involved inHSP70_1, HSP70_2, HSP70_3stress response262-263CT13852CG4202 Sas10 Sas10(NM_023054) disrupter of259silencing SAS10 [Mus musculus]264-265CT14019CG4300 spermidineSAM_BIND(AJ009865) spermine synthase276synthase[Takifugu rubripes]266-267CT14119CG4300 spermidineSAM_BIND(AJ009865) spermine synthase276synthase[Takifugu rubripes]268-269CT13914CG4317 Mipp2 Mipp2,CYTOCHROME_B_QOMus musculus ‘multiple inositolmultiple inositol-polyphosphate phosphatase’polyphosphateEMBL: AF046908phosphatase 2270-271CT14464CG4453 transporter, anZF_RANBP, zf-RanBP14578 nucleoporin Nup153300endopeptidase involved inhomolog - African clawed frogbehavior which is a(fragment)component of the nucleus272-273CT14586CG4481 Glu-RIB ionANF_receptor,Mus musculus ‘glutamatechannel-alpha-amino-3-CHANNEL_PORE_K,receptor channel a3 subunit’hydroxy-5-methyl-4-NLS_BP, SBP_GLUR, lig_chanEMBL: AB022342isoxazole propionateselective glutamatereceptor; ionotropicglutamate receptor274-275CT14874CG4590 inx2 inx2,InnexinSchistocerca americananeurotransmitter‘innexin-2’ EMBL: 115854_1transporter, Dm-inx pasrelated protein 33276-277CT15952CG4974 dally NOT cellGlypican(NM_004466) glypican 5186adhesion molecule;[Homo sapiens]heparin sulfateproteoglycan; Dally278-279CT16489CG5147 unknownnone280-281CT16663CG5208noneBcDNA: LD27979unknown282-283CT17394CG5485 high affinity(AF349043) sulfate anion340sulfate permease, sulfatetransporter-1 [Mus musculus]transporter284-285CT17382CG5486 Ubp64E(NM_063285) ubiquitin358Ubiquitin-specificcarboxyl-terminal hydrolaseprotease 64E[Caenorhabditis286-287CT17448CG5505 endopeptidase,UCH-1, UCH-2, UCH_2_1,(XM_027039) KIAA1453254ubiquitin-specificUCH_2_2, UCH_2_3protein [Homo sapiens]protease, involved inprocess ofdeubiquitylation288-289CT17938CG5684 non-specificQ9UIV1|CNO7_HUMAN376RNA polymerase IICCR4-NOT transcriptiontranscription factorcomplex, subunit 7 (CCR4-associated factor290-291CT17971CG5722 NPC1 dmNPC1,5TM_BOX, NLS_BP(NM_000271) Niemann-Pick1061transmembrane receptordisease, type C1 [Homo sapiens]292-293CT18192CG5797 cytoskeletalPRO_RICH(AB051482) KIAA1695 protein541binding protein[Homo sapiens]294-295CT18619CG5939 Prm Para,NLS_BP(AF317670) paramyosin989Paramyosin, structural[Sarcoptes scabiei]protein of muscle, motor296-297CT18969CG6058 Ald fructose-ALDOLASE_CLASS_I,Mus musculus Aldo1bisphosphate aldolase,NLS_BP, glycolytic_enzyMGI: 87994involved in process ofglycolysis298-299CT19788CG6335 histidine--tRNAAA_TRNA_LIGASE_II_1,(NM_008214) histidyl tRNA641ligaseAA_TRNA_LIGASE_II_2,synthetase [Mus musculus]WHEP-TRS, tRNA-synt_2b300-301CT19850CG6367 serine-type(AF053921) trypsin-like serine163endopeptidaseprotease [Ctenocephalides felis]302-303CT19962CG6400 unknownBROMODOMAIN,Q9NSI6|WDR9_HUMAN WD-916BROMODOMAIN_2,REPEAT PROTEIN 9GPROTEINBRPT, NLS_BP,WD40, WD40_REGION,WD_REPEATS, bromodomain304-305CT20122CG6470 unknownZINC_FINGER_C2H2,noneZINC_FINGER_C2H2_2, zf-C2H2306-307CT20269CG6513 signal(NM_019561) endosulfine91.3transductionalpha; alpha-endosulfine [Mus musculus]308-309CT21021CG6774 tracheal(NM_023037) hypothetical1006gasfilling mutantprotein CG003 [Homo sapiens]310-311CT21292CG6874 unknownnone312-313CT43217CG6928 SulfateSulfate_transptransporter314-315CT21476CG6930 unknownNLS_BP,Caenorhabditis elegans ‘containsZINC_FINGER_C2H2,strong similarity to a C2H2-typeZINC_FINGER_C2H2_2, zf-zinc finger’ EMBL: AF000194C2H2316-317CT21525CG6946 RNA bindingRBD, rrmRattus norvegicus‘ribonucleoprotein F’EMBL: AB022209318-319CT21704CG7014 structuralRIBOSOMAL_S7,(NM_001009) ribosomal protein347protein of ribosome,Ribosomal_S7S5; 40S ribosomal protein S5Process protein[Homobiosynthesis320-321CT22195CG7187 DNA binding(AY026310) single stranded351DNA binding protein-1 [Homosapiens]322-323CT22253CG7215 ubiquitinUBIQUITIN_2, ubiquitinP21126|UBLG_MOUSE75.5Ubiquitin-like protein GDX(Ubiquitin-like protein 4)324-325CT22861CG7434 RpL22 ribosomalANTIFREEZEI(AF400188) ribosomal protein165protein L22L22 [Spodoptera frugiperda]326-327CT23083CG7552 unknownATP_GTP_A,Homo sapiens ‘65 KD YES-WW_DOMAIN_1,ASSOCIATED PROTEINWW_DOMAIN_2,(YAP65)’ SWP: P46937WW_rsp5_WWP328-329CT23596CG7757 similarity toNLS_BP(NM_004698) U4/U6-associated520U4/U6-associated RNARNA splicing factor [Homosplicing factorsapiens]330-331CT23626CG7770 cochaperonin in(NM_010385) H2-K region106process of ‘de novo’expressed gene 2 [Musprotein foldingmusculus]332-333CT23882CG7901 PP2A-B′ proteinANTIFREEZEIMus musculus ‘proteinphosphatase, proteinphosphatase 2A B′a3 regulatoryphosphatase type 2Asubunit’ EMBL: U37353regulator334-335CT41698CG7958 unknown(AB033050) KIAA1224 protein427[Homo sapiens]336-337CT23982CG7958 unknown(AB033050) KIAA1224 protein427[Homo sapiens]338-339CT23998CG7983 guanylate kinasePRO_RICH(AF411837) transcription214repressor p66 [Mus musculus]340-341CT24094CG8031 unknown(BC013819) CGI-27 protein394[Mus musculus]342-343CT24122CG8037 ELL, DNA-Gallus gallus ‘OCCLUDIN’directed RNA polymeraseSWP: Q91049III;344-345CT24346CG8148 timeout timeout(NM_003920) timeless149(Drosophila) homolog [Homosapiens]346-347CT24393CG8189 ATPsyn-bAcetyltransf(AF187862) ATP synthase213ATPsyn-b Fo-ATPsubunit B [Xenopus laevis]synthase subunit b348-349CT24437CG8231 T-complexCHAPERONIN60,O77622|TCPZ_RABIT T-754protein 1, zeta-subunit,TCOMPLEXTCP1, TCP1_1,COMPLEX PROTEIN 1, ZETAchaperoneTCP1_2, TCP1_3, cpn60_TCP1SUBUNIT (TCP-1-ZETA)(CCT-ZETA)350-351CT18257CG8322 ATPCL ATP-SUCCINYL_COA_LIG_1,(U18197) ATP: citrate lyase1555citrate (pro-S)-lyaseSUCCINYL_COA_LIG_2,[Homo sapiens]SUCCINYL_COA_LIG_3,ligase-CoA352-353CT24731CG8439 Cct5 Cct5, T-(XM_052313) chaperonin791complex Chaperonin 5,containing TCP1, subunit 5tracheal gasfilling mutant(epsilon) [Homo354-355CT24823CG8484 TranscriptionZINC_FINGER_C2H2,(NM_058230) zinc finger167factorZINC_FINGER_C2H2_2, zf-protein 354B [Homo sapiens]C2H2356-357CT25072CG8655 CDC receptorAA_TRNA_LIGASE_II_2,(AF005209) HsCdc7 [Homo216signaling proteinPROTEIN_KINASE_DOM,sapiens]serine/threonine kinasePROTEIN_KINASE_ST,pkinase358-359CT25274CG8759 Nacalpha; NACHomo sapiens & agrprotein alpha subunit,PIR: S49326component of the nascentpolypeptide-associatedcomplex360-361CT25472CG8870 endopeptidase,ANTENNAPEDIA,Caenorhabditis elegans ‘similarmonophenolCHYMOTRYPSIN,to plasminogen and to trypsin-monooxygenase activatorTRYPSIN_CATAL,like serine proteases’TRYPSIN_HIS,EMBL: U29380TRYPSIN_SER, trypsin362-363CT25624CG8922 RpS5 RibosomalRIBOSOMAL_S7,(Y12431) 5S ribosomal protein353protein S5Ribosomal_S7[Mus musculus]364-365CT8969CG9165 enzyme,PORPHBDMNASE,P08397|HEM3_HUMAN287hydroxymethylbilanePorphobil_deamPORPHOBILINOGENsynthaseDEAMINASE(HYDROXYMETHYLBILANESYNTHASE) (HMBS)366-367CT27084CG9591 unknown(XM_043261) KIAA1698116protein [Homo sapiens]368-369CT27543CG9748 cap Belle, ATP1705301A ATP dependent723dependent helicaseRNA helicase [Xenopus laevis]370-371CT27750CG9821 unknownnone372-373CT27796CG9901 Arp14D Actin-ACTIN, ACTINS_ACT_LIKE,P53488|ARP2_CHICK ACTIN-678related protein 14D, arp2actinLIKE PROTEIN 2 (ACTIN-LIKE PROTEIN ACTL)374-375CT27906CG9910 katanin-80(AF052433) katanin p80 subunit231katanin 80, microtubule[Strongylocentrotus purpuratus]severing which is acomponent of the katanin376-377CT27940CG9924 transcriptionBTB, MATH(NM_003563) speckle-type POZ599factorprotein [Homo sapiens]378-379CT27993CG9946 eIF-2alpha;NLS_BP, S1(NM_131800) eIF2 alpha376Eukaryotic initiationsubunit [Danio rerio]factor 2A; translationinitiation factor380-381CT20536CG6606 unknownATPASE_ALPHA_BETA,(AB020664) KIAA0857 protein122ATP_GTP_A, C2, NLS_BP,[Homo sapiens]RECEPTOR_CYTOKINES_2


DEFINITIONS

For clarity, certain terms used in the specification are defined and used as follows:


“Associated with/operatively linked” refer to two nucleic acid sequences that are related physically or functionally. For example, a promoter or regulatory DNA sequence is said to be “associated with” a DNA sequence that codes for an RNA or a protein if the two sequences are operatively linked, or situated such that the regulator DNA sequence will affect the expression level of the coding or structural DNA sequence.


A “chimeric construct” is a recombinant nucleic acid sequence in which a promoter or regulatory nucleic acid sequence is operatively linked to, or associated with, a nucleic acid sequence that codes for an mRNA or which is expressed as a protein, such that the regulatory nucleic acid sequence is able to regulate transcription or expression of the associated nucleic acid sequence. The regulatory nucleic acid sequence of the chimeric construct is not normally operatively linked to the associated nucleic acid sequence as found in nature.


Co-factor: natural reactant, such as an organic molecule or a metal ion, required in an enzyme-catalyzed reaction. A co-factor is e.g. NAD(P), riboflavin (including FAD and FMN), folate, molybdopterin, thiamin, biotin, lipoic acid, pantothenic acid and coenzyme A, S-adenosylmethionine, pyridoxal phosphate, ubiquinone, menaquinone. Optionally, a co-factor can be regenerated and reused.


A “coding sequence” is a nucleic acid sequence that is transcribed into RNA such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. Preferably the RNA is then translated in an organism to produce a protein.


Complementary: “complementary” refers to two nucleotide sequences that comprise antiparallel nucleotide sequences capable of pairing with one another upon formation of hydrogen bonds between the complementary base residues in the antiparallel nucleotide sequences.


“Conservatively modified variations” of a particular nucleic acid sequence refers to those nucleic acid sequences that encode identical or essentially identical amino acid sequences, or where the nucleic acid sequence does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given polypeptide. For instance the codons CGT, CGC, CGA, CGG, AGA, and AGG all encode the amino acid arginine. Thus, at every position where an arginine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded protein. Such nucleic acid variations are “silent variations” which are one species of “conservatively modified variations.” Every nucleic acid sequence described herein which encodes a protein also describes every possible silent variation, except where otherwise noted. One of skill will recognize that each codon in a nucleic acid (except ATG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule by standard techniques. Accordingly, each “silent variation” of a nucleic acid which encodes a protein is implicit in each described sequence.


Furthermore, one of skill will recognize that individual substitutions deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in an encoded sequence are “conservatively modified variations,” where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following five groups each contain amino acids that are conservative substitutions for one another: Aliphatic: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I); Aromatic: Phenylalanine (F), Tyrosine (Y), Tryptophan (W); Sulfur-containing: Methionine (M), Cysteine (C); Basic: Arginine R), Lysine (K), Histidine (H); Acidic: Aspartic acid (D), Glutamic acid (E), Asparagine (N), Glutamine (Q). See also, Creighton (1984) Proteins, W. H. Freeman and Company. In addition, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence are also “conservatively modified variations.”


DNA Shuffling: DNA shuffling is a method to rapidly, easily and efficiently introduce mutations or rearrangements, preferably randomly, in a DNA molecule or to generate exchanges of DNA sequences between two or more DNA molecules, preferably randomly. The DNA molecule resulting from DNA shuffling is a shuffled DNA molecule that is a non-naturally occurring DNA molecule derived from at least one template DNA molecule. The shuffled DNA encodes an enzyme modified with respect to the enzyme encoded by the template DNA, and preferably has an altered biological activity with respect to the enzyme encoded by the template DNA.


Enzyme/Protein Activity: means herein the ability of an enzyme (or protein) to catalyze the conversion of a substrate into a product. A substrate for the enzyme comprises the natural substrate of the enzyme but also comprises analogues of the natural substrate, which can also be converted, by the enzyme into a product or into an analogue of a product. The activity of the enzyme is measured for example by determining the amount of product in the reaction after a certain period of time, or by determining the amount of substrate remaining in the reaction mixture after a certain period of time. The activity of the enzyme is also measured by determining the amount of an unused co-factor of the reaction remaining in the reaction mixture after a certain period of time or by determining the amount of used co-factor in the reaction mixture after a certain period of time. The activity of the enzyme is also measured by determining the amount of a donor of free energy or energy-rich molecule (e.g. ATP, phosphoenolpyruvate, acetyl phosphate or phosphocreatine) remaining in the reaction mixture after a certain period of time or by determining the amount of a used donor of free energy or energy-rich molecule (e.g. ADP, pyruvate, acetate or creatine) in the reaction mixture after a certain period of time.


Essential: an “essential” Drosophila melanogaster nucleotide sequence is a nucleotide sequence encoding a protein such as e.g. a biosynthetic enzyme, receptor, signal transduction protein, structural gene product, or transport protein that is essential to the growth or survival of the insect.


Expression Cassette: “Expression cassette” as used herein means a DNA sequence capable of directing expression of a particular nucleotide sequence in an appropriate host cell, comprising a promoter operatively linked to the nucleotide sequence of interest which is operatively linked to termination signals. It also typically comprises sequences required for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest but may also code for a functional RNA of interest, for example antisense RNA or a nontranslated RNA, in the sense or antisense direction. The expression cassette comprising the nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components. The expression cassette may also be one which is naturally occurring but has been obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous with respect to the host, i.e., the particular DNA sequence of the expression cassette does not occur naturally in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation event. The expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or of an inducible promoter which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, such as an insect, the promoter can also be specific to a particular tissue or organ or stage of development.


Gene: the term “gene” is used broadly to refer to any segment of DNA associated with a biological function. Thus, genes include coding sequences and/or the regulatory sequences required for their expression. Genes also include nonexpressed DNA segments that, for example, form recognition sequences for other proteins. Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have desired parameters.


Heterologous/exogenous: The terms “heterologous” and “exogenous” when used herein to refer to a nucleic acid sequence (e.g. a DNA sequence) or a gene, refer to a sequence that originates from a source foreign to the particular host cell or, if from the same source, is modified from its original form. Thus, a heterologous gene in a host cell includes a gene that is endogenous to the particular host cell but has been modified through, for example, the use of DNA shuffling. The terms also include non-naturally occurring multiple copies of a naturally occurring DNA sequence. Thus, the terms refer to a DNA segment that is foreign or heterologous to the cell, or homologous to the cell but in a position within the host cell nucleic acid in which the element is not ordinarily found. Exogenous DNA segments are expressed to yield exogenous polypeptides.


A “homologous” nucleic acid (e.g. DNA) sequence is a nucleic acid (e.g. DNA) sequence naturally associated with a host cell into which it is introduced.


The terms “identical” or percent “identity” in the context of two or more nucleic acid or protein sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.


Inhibitor: a chemical substance that inactivates the enzymatic activity of an enzyme (or protein) of interest The term “insecticide” is used herein to define an inhibitor when applied to an insect at any stage of development


Insecticide: a chemical substance used to kill or inhibit the growth or viability of insects at any stage of development.


Interaction: quality or state of mutual action such that the effectiveness or toxicity of one protein or compound on another protein is inhibitory (antagonists) or enhancing (agonists).


A nucleic acid sequence is “isocoding with” a reference nucleic acid sequence when the nucleic acid sequence encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the reference nucleic acid sequence.


An “isolated” nucleic acid molecule or an isolated enzyme is a nucleic acid molecule or enzyme that, by the hand of man, exists apart from its native environment and is therefore not a product of nature. An isolated nucleic acid molecule or enzyme may exist in a purified form or may exist in a non-native environment such as, for example, a recombinant host cell.


Mature Protein: protein that is normally targeted to a cellular organelle and from which the transit peptide has been removed.


Minimal Promoter: promoter elements, particularly a TATA element, that are inactive or that have greatly reduced promoter activity in the absence of upstream activation. In the presence of a suitable transcription factor, the minimal promoter functions to permit transcription.


Modified Enzyme Activity: enzyme activity different from that which naturally occurs in an insect (i.e. enzyme activity that occurs naturally in the absence of direct or indirect manipulation of such activity by man), which is tolerant to inhibitors that inhibit the naturally occurring enzyme activity.


Native: refers to a gene that is present in the genome of an untransformed insect cell.


Naturally occurring: the term “naturally occurring” is used to describe an object that can be found in nature as distinct from being artificially produced by man. For example, a protein or nucleotide sequence present in an organism (including a virus), which can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory, is naturally occurring.


Nucleic acid: the term “nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides which have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g. degenerate codon substitutions) and complementary sequences and as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and/or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19: 5081 (1991); Ohtsuka et al., J. Biol. Chem. 260: 2605-2608 (1985); Rossolini et al., Mol. Cell Probes 8: 91-98 (1994)). The terms “nucleic acid” or “nucleic acid sequence” may also be used interchangeably with gene, cDNA, and mRNA encoded by a gene.


“ORF” means open reading frame.


Purified: the term “purified,” when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It is preferably in a homogeneous state although it can be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein which is the predominant species present in a preparation is substantially purified. The term “purified” denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel. Particularly, it means that the nucleic acid or protein is at least about 50% pure, more preferably at least about 85% pure, and most preferably at least about 99% pure.


Two nucleic acids are “recombined” when sequences from each of the two nucleic acids are combined in a progeny nucleic acid. Two sequences are “directly” recombined when both of the nucleic acids are substrates for recombination. Two sequences are “indirectly recombined” when the sequences are recombined using an intermediate such as a cross-over oligonucleotide. For indirect recombination, no more than one of the sequences is an actual substrate for recombination, and in some cases, neither sequence is a substrate for recombination.


“Regulatory elements” refer to sequences involved in controlling the expression of a nucleotide sequence. Regulatory elements comprise a promoter operatively linked to the nucleotide sequence of interest and termination signals. They also typically encompass sequences required for proper translation of the nucleotide sequence.


Significant Increase: an increase in enzymatic activity that is larger than the margin of error inherent in the measurement technique, preferably an increase by about 2-fold or greater of the activity of the wild-type enzyme in the presence of the inhibitor, more preferably an increase by about 5-fold or greater, and most preferably an increase by about 10-fold or greater.


Substantially identical: the phrase “substantially identical,” in the context of two nucleic acid or protein sequences, refers to two or more sequences or subsequences that have at least 60%, preferably 80%, more preferably 90, even more preferably 95%, and most preferably at least 99% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. Preferably, the substantial identity exists over a region of the sequences that is at least about 50 residues in length, more preferably over a region of at least about 100 residues, and most preferably the sequences are substantially identical over at least about 150 residues. In an especially preferred embodiment, the sequences are substantially identical over the entire length of the coding regions. Furthermore, substantially identical nucleic acid or protein sequences perform substantially the same function.


For sequence comparison, typically one sequence acts as a reference sequence to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.


Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2: 482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48: 443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis,), or by visual inspection (see generally, Ausubel et al., infra).


One example of an algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul et al., J. Mol. Biol. 215: 403410 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information on the world wide web at ncbi.nlm.nih.gov/. This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., 1990). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when the cumulative alignment score falls off by the quantity X from its maximum achieved value, the cumulative score goes to zero or below due to the accumulation of one or more negative-scoring residue alignments, or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=−4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).


In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90: 5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid sequence to the reference nucleic acid sequence is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.


Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions. The phrase “hybridizing specifically to” refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA. “Bind(s) substantially” refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target nucleic acid sequence.


“Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and Northern hybridizations are sequence dependent, and are different under different environmental parameters. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen (1993) Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes part I chapter 2 “Overview of principles of hybridization and the strategy of nucleic acid probe assays” Elsevier, N.Y. Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Typically, under “stringent conditions” a probe will hybridize to its target subsequence, but to no other sequences.


The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the Tm for a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42° C., with the hybridization being carried out overnight. An example of highly stringent wash conditions is 0.1 5M NaCl at 72° C. for about 15 minutes. An example of stringent wash conditions is a 0.2×SSC wash at 65° C. for 15 minutes (see, Sambrook, infra, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is 1×SSC at 45° C. for 15 minutes. An example low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6×SSC at 40° C. for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30° C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2× (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the proteins that they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code.


The following are examples of sets of hybridization/wash conditions that may be used to clone homologous nucleotide sequences that are substantially identical to reference nucleotide sequences of the present invention: a reference nucleotide sequence preferably hybridizes to the reference nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. with washing in 2×SSC, 0.1% SDS at 50° C., more desirably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. with washing in 1×SSC, 0.1% SDS at 50° C., more desirably still in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. with washing in 0.5×SSC, 0.1% SDS at 50° C., preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. with washing in 0.1×SSC, 0.1% SDS at 50° C., more preferably in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO4, 1 mM EDTA at 50° C. with washing in 0.1×SSC, 0.1% SDS at 65° C.


A further indication that two nucleic acid sequences or proteins are substantially identical is that the protein encoded by the first nucleic acid is immunologically cross reactive with, or specifically binds to, the protein encoded by the second nucleic acid. Thus, a protein is typically substantially identical to a second protein, for example, where the two proteins differ only by conservative substitutions.


The phrase “specifically (or selectively) binds to an antibody,” or “specifically (or selectively) immunoreactive with,” when referring to a protein or peptide, refers to a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein. For example, antibodies raised to the protein with the amino acid sequence encoded by any of the nucleic acid sequences of the invention can be selected to obtain antibodies specifically immunoreactive with that protein and not with other proteins except for polymorphic variants. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid-phase ELISA immunoassays, Western blots, or immunohistochemistry are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York “Harlow and Lane”), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Typically a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.


A “subsequence” refers to a sequence of nucleic acids or amino acids that comprise a part of a longer sequence of nucleic acids or amino acids (e.g., protein) respectively.


“Synthetic” refers to a nucleotide sequence comprising structural characters that are not present in the natural sequence. For example, an artificial sequence that resembles more closely the G+C content and the normal codon distribution of dicot and/or monocot genes is said to be synthetic.


Substrate: a substrate is the molecule that an enzyme naturally recognizes and converts to a product in the biochemical pathway in which the enzyme naturally carries out its function, or is a modified version of the molecule, which is also recognized by the enzyme and is converted by the enzyme to a product in an enzymatic reaction similar to the naturally-occurring reaction.


Target gene: A “target gene” is any gene in an insect cell. For example, a target gene is a gene of known function or is a gene whose function is unknown, but whose total or partial nucleotide sequence is known. Alternatively, the function of a target gene and its nucleotide sequence are both unknown. A target gene is a native gene of the insect cell or is a heterologous gene that had previously been introduced into the insect cell or a parent cell of said insect cell, for example by genetic transformation. A heterologous target gene is stably integrated in the genome of the insect cell or is present in the insect cell as an extrachromosomal molecule, e.g. as an autonomously replicating extrachromosomal molecule.


Transformation: a process for introducing heterologous DNA into a cell, tissue, or insect Transformed cells, tissues, or insects are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof.


“Transformed,” “transgenic,” and “recombinant” refer to a host organism such as a bacterium or a plant into which a heterologous nucleic acid molecule has been introduced. The nucleic acid molecule can be stably integrated into the genome of the host or the nucleic acid molecule can also be present as an extrachromosomal molecule. Such an extrachromosomal molecule can be auto-replicating. Transformed cells, tissues, or plants are understood to encompass not only the end product of a transformation process, but also transgenic progeny thereof. A “non-transformed,” “non-transgenic,” or “non-recombinant” host refers to a wild-type organism, e.g., a bacterium or plant, which does not contain the heterologous nucleic acid molecule.


Viability: “viability” as used herein refers to a fitness parameter of an insect. Insects are assayed for their homozygous performance of Drosophila development, indicating which proteins are indispensable to maintain life in Drosophila.







DETAILED DESCRIPTION OF THE INVENTION

I. Identification Of Essential Drosophila melanogaster Nucleotide Sequences Using Transposable Element Insertion Mutagenesis


As shown in Table 2 and the examples below, the identification of novel nucleotide sequences, as well as the essentiality of the nucleotide sequences for normal insect viability, have been demonstrated in Drosophila using P-element transposable insertion mutagenesis. Having established the essentiality of the function of the encoded proteins in Drosophila and having identified the nucleotide sequences encoding these essential proteins, the inventors thereby provide an important and sought-after tool for new insecticide development.


A lethal phenotype caused by insertion of a P-element indicates that the affected nucleotide sequence codes for an essential protein in the insect. The characterization of the insertion site using flanking sequence DNA is needed to associate an individual lethal line with specific nucleotide sequences. Genomic DNA adjacent to the 5′ and/or 3′ end of the P-element from the insertion line is generated using inverse PCR.

TABLE 2Method of validation of nucleic acid sequences as essentialSEQ IDNOvalidation method14dsRNA and p-element disruption16p-element disruption18p-element disruption20p-element disruption22p-element disruption24p-element disruption26p-element disruption28p-element disruption30dsRNA32p-element disruption34p-element disruption36p-element disruption38p-element disruption40p-element disruption42dsRNA44p-element disruption46p-element disruption48p-element disruption50p-element disruption52DsRNA54p-element disruption56p-element disruption58p-element disruption60p-element disruption62p-element disruption64p-element disruption66p-element disruption68DsRNA70DsRNA72DsRNA74p-element disruption76p-element disruption78p-element disruption80p-element disruption82p-element disruption84p-element disruption86DsRNA88p-element disruption90p-element disruption92p-element disruption94p-element disruption96p-element disruption98p-element disruption100p-element disruption102p-element disruption104p-element disruption106dsRNA and p-element disruption108p-element disruption110DsRNA112p-element disruption114DsRNA116p-element disruption118p-element disruption120p-element disruption122p-element disruption124p-element disruption126p-element disruption128p-element disruption130p-element disruption132p-element disruption134p-element disruption136p-element disruption138p-element disruption140p-element disruption142p-element disruption144p-element disruption146p-element disruption148p-element disruption150p-element disruption152p-element disruption154p-element disruption156p-element disruption158p-element disruption160DsRNA162p-element disruption164p-element disruption166p-element disruption168p-element disruption170p-element disruption172p-element disruption174p-element disruption176p-element disruption178p-element disruption180p-element disruption182p-element disruption184p-element disruption186p-element disruption188p-element disruption190p-element disruption192p-element disruption194DsRNA196p-element disruption198p-element disruption200p-element disruption202p-element disruption204DsRNA206p-element disruption208p-element disruption210p-element disruption212p-element disruption214DsRNA216p-element disruption218p-element disruption220p-element disruption222DsRNA224p-element disruption226p-element disruption227p-element disruption228p-element disruption230p-element disruption232p-element disruption234p-element disruption236p-element disruption238p-element disruption240p-element disruption242p-element disruption244DsRNA246p-element disruption248p-element disruption250p-element disruption252p-element disruption254p-element disruption256p-element disruption258p-element disruption260p-element disruption262p-element disruption264p-element disruption266p-element disruption268p-element disruption270p-element disruption272dsRNA and p-element disruption274p-element disruption276p-element disruption278p-element disruption280p-element disruption282p-element disruption284p-element disruption286DsRNA288DsRNA290p-element disruption292p-element disruption294p-element disruption296DsRNA298DsRNA300p-element disruption302p-element disruption304p-element disruption306p-element disruption308p-element disruption310p-element disruption312p-element disruption314p-element disruption316p-element disruption318p-element disruption320p-element disruption322p-element disruption324p-element disruption326p-element disruption328p-element disruption330p-element disruption332p-element disruption334p-element disruption336p-element disruption338p-element disruption340p-element disruption342dsRNA and p-element disruption344DsRNA346p-element disruption348dsRNA and p-element disruption350DsRNA352dsRNA and p-element disruption354p-element disruption356p-element disruption358dsRNA and p-element disruption360p-element disruption362p-element disruption364p-element disruption366p-element disruption368DsRNA370p-element disruption372p-element disruption374p-element disruption376p-element disruption378p-element disruption380p-element disruption


I. Determining the Complete Coding Sequences of the Essential Drosophila Nucleotide Sequences


The essential Drosophila nucleotide sequences are identified by isolating nucleotide sequences flanking the P-element insertion and aligning that sequence with genomic Drosophila sequence obtained from the Celera Drosophila database. The protein prediction for each genomic region is obtained by use of an exon algorithm program such as GeneMark. All exon algorithm programs currently used for prediction of proteins are susceptible to inaccuracies, including incomplete predictions of coding sequences, missing alternative splice variants, combining of nearby exons of adjacent genes, and mistranslation at intron-exon borders. The prediction of a complete coding sequence can be confirmed by several methods including polymerase chain reaction (PCR) amplification using the 5′ and 3′ sequence to verify the message, reverse transcription PCR (rtPCR) using an oligonucleotide internal sequence to identify the 5′ and/or 3′ end, and screening of cDNA libraries from insect tissues with probes made from a particular sequence to isolate a true full-length clone. To confirm that the message size is accurate, a Northern blot can be hybridized with a probe from the nucleotide sequence. In addition, matches to the Drosophila EST database helps to confirm existence of message and gives information about the temporal and spatial pattern of expression. Mutation-causing P elements are known to preferentially cluster in the 5′ region of affected genes (Spradling et al, Proc. Natl. Acad. Sci. USA 92: 10824-10830 (1995)), a tendency that increases the chance of recovering overlaps between short flanking sequences and 5′ ESTs. The present invention therefore provides a number of essential nucleotide sequences as well as the amino acid sequences encoded thereby. cDNA clone sequences are set forth in even numbered SEQ ID NOs:14-380. The corresponding encoded amino acid sequences are set forth in odd numbered SEQ ID NOs:15-381.


The isolated gene sequences disclosed herein may be manipulated according to standard genetic engineering techniques to suit any desired purpose. For example, an entire Drosophila gene sequence or portions thereof may be used as a probe capable of specifically hybridizing to coding sequences and messenger RNAs. To achieve specific hybridization under a variety of conditions, such probes include, e.g. sequences that are unique among insect nucleotide sequences for a particular protein of interest and are at least 10 nucleotides in length, preferably at least 20 nucleotides in length, and most preferably at least 50 nucleotides in length. Such probes are used to amplify and analyze related nucleotide sequences from a chosen organism via PCR. This technique is useful to isolate additional insect nucleotide sequences from a desired organism or as a diagnostic assay to determine the presence of particular nucleotide sequences in an organism. This technique also is used to detect the presence of altered nucleotide sequences associated with a particular condition of interest such as insecticide tolerance, poor health, etc.


Gene-specific hybridization probes also are used to quantify levels of a particular gene mRNA in an insect using standard techniques such as Northern blot analysis. This technique is useful as a diagnostic assay to detect altered levels of gene expression that are associated with particular conditions such as enhanced tolerance to insecticides that target a particular gene.


I.A. Identification of Essential Drosophila melannogaster Nucleotide Sequences Using RNAi


RNA-mediated interference (RNAi) is a recently discovered method to determine gene function in a number of organisms, wherein double-stranded RNA (dsRNA) directs gene-specific, post-transcriptional silencing. See, e.g., Kuwabara & Olson (2000) Parasitol Today 16(8):347-349; Bass (2000) Cell 101(3):235-238; Hunter (2000) Curr Biol 10(4):R137-140; Bosher & Labouesse (2000) Nat Cell Biol 2(2):E31-36; Sharp (1999) Genes Dev 13(2):139-141. The double-stranded RNA molecule can be synthesized in vitro and then introduced into the organism by injection or other methods. Alternatively, a heritable transgene exhibiting dyad symmetry can provide a transcript that folds as a hairpin structure. Methods for examining gene functions using dsRNAi in Drosophila are disclosed in Example 4a and further in Kennerdell & Carthew (2000) Nat Biotech 18(8):896-898; Lam & Thummel (2000) Curr Biol 10(16):957-963; Misquitta & Paterson (1999) Proc Natl Acad Sci USA 96 (4):1451-1456. The present invention describes RNA-mediated interference of sequences listed in Table 2 and Table 6. Double-stranded RNA complementary to each sequence was synthesized in vitro and injected into early Drosophila embryos, as described in Example 4a. Development of injected embryos was assessed by scoring: (a) morphological criteria using a light microscope (Campos-Ortega & Hartenstein (1985) The Embryonic Development of Drosophila melanogaster, Springer-Verlag, Berlin), (b) embryo hatching to become a larvae, (c) puparium formation, and (d) eclosion of the pupae as an adult fly, as indicated in Table 6 herein below. Buffer-injected embryos were injected and monitored in parallel as a control. The percentage of embryos injected with dsRNA that survive to the adult stage is depicted in set forth in Table 6.


Essential genes were identified as those resulting in a percent viable adults below 38% when disrupted by RNAi. This threshold was determined by comparison to multiple buffer-injected controls.


II. Recombinant Production of Protein and Uses Thereof


For recombinant production of a protein of the invention in a host organism, a nucleotide sequence encoding the protein is inserted into an expression cassette designed for the chosen host and introduced into the host where it is recombinantly produced. The choice of the specific regulatory sequences such as promoter, signal sequence, 5′ and 3′ untranslated sequence, and enhancer appropriate for the chosen host is within the level of the skill of the routineer in the art. The resultant molecule, containing the individual elements linking in the proper reading frame, is inserted into a vector capable of being transformed into the host cell. Suitable expression vectors and methods for recombinant production of proteins are well known for host organisms such as E. coli, yeast, and insect cells (see, e.g., Lucknow and Summers, Bio/Technol. 6:47 (1988)). Additional suitable expression vectors are baculovirus expression vectors, e.g., those derived from the genome of Autographica californica nuclear polyhedrosis virus (AcMNPV). A preferred baculovirus/insect system is PVL1392(3) used to transfect Spodoptera frugiperda SF9 cells (ATCC) in the presence of linear Autographica californica baculovirus DNA (Phramingen, San Diego, Calif.). The resulting virus is used to infect HighFive Tricoplusia ni cells (Invitrogen, La Jolla, Calif.).


Recombinantly produced proteins are isolated and purified using a variety of standard techniques. The actual techniques used vary depending upon the host organism used, whether the protein is designed for secretion, and other such factors. Such techniques are well known to the skilled artisan (see, e.g. chapter 16 of Ausubel, F. et al., “Current Protocols in Molecular Biology”, pub. by John Wiley & Sons, Inc. (1994).


IV. Assays for Characterizing the Proteins


Recombinantly produced proteins are useful for a variety of purposes. For example, they can be used in in vitro assays to screen known insecticidal chemicals whose target has not been identified to determine if they inhibit protein activity. Such in vitro assays may also be used as more general screens to identity chemicals that inhibit such protein activity and that are therefore novel insecticide candidates. Recombinantly produced proteins may also be used to elucidate the complex structure of these molecules and to further characterize their association with known inhibitors in order to rationally design new inhibitory insecticides. Alternatively, the recombinant protein can be used to isolate antibodies or peptides that modulate the activity and are useful in transgenic solutions.


V. In Vivo Inhibitor Assay: Discovery of Small Molecule Ligands that Interact with Proteins of Unknown Function.


Having identified a protein as a potential insecticide target based on its essentiality for insect viability, a next step is to develop an assay that allows screening large numbers of chemicals to determine which ones interact with the protein. Although it is straightforward to develop assays for proteins of known function, developing assays with proteins of unknown functions can be more difficult.


To address this issue, novel technologies are used that can detect interactions between a protein and a ligand without knowing the biological function of the protein. A short description of three methods is presented, including fluorescence correlation spectroscopy, surface-enhanced laser desorption/ionization, and biacore technologies. In addition to those descibed here, there are additional methods that are currently being developed that are also amenable to automated, large-scale screening.


Fluorescence Correlation Spectroscopy (FCS) theory was developed in 1972 but it is only in recent years that the technology to perform FCS became available (Madge et al. (1972) Phys. Rev. Lett., 29: 705-708; Maiti et al. (1997) Proc. Natl. Acad. Sci. USA, 94: 11753-11757). FCS measures the average diffusion rate of a fluorescent molecule within a small sample volume. The sample size can be as low as 103 fluorescent molecules and the sample volume as low as the cytoplasm of a single bacterium. The diffusion rate is a function of the mass of the molecule and decreases as the mass increases. FCS can therefore be applied to protein-ligand interaction analysis by measuring the change in mass and therefore in diffusion rate of a molecule upon binding. In a typical experiment, the target to be analyzed is expressed as a recombinant protein with a sequence tag, such as a poly-histidine sequence, inserted at the N- or C-terminus. The expression takes place in E. coli, yeast or insect cells. The protein is purified by chromatography. For example, the poly-histidine tag can be used to bind the expressed protein to a metal chelate column such as Ni2+ chelated on iminodiacetic acid agarose. The protein is then labeled with a fluorescent tag such as carboxytetramethylrhodamine or BODIPY® (Molecular Probes, Eugene, Oreg.). The protein is then exposed in solution to the potential ligand, and its diffusion rate is determined by FCS using instrumentation available from Carl Zeiss, Inc. (Thornwood, N.Y.). Ligand binding is determined by changes in the diffusion rate of the protein.


Surface-Enhanced Laser Desorption/Ionization (SELDI) was invented by Hutchens and Yip during the late 1980's (Hutchens and Yip (1993) Rapid Commun. Mass Spectrom. 7: 576-580). When coupled to a time-of-flight mass spectrometer (TOF), SELDI provides means to rapidly analyze molecules retained on a chip. It can be applied to ligand-protein interaction analysis by covalently binding the target protein on the chip and analyze by MS the small molecules that bind to this protein (Worrall et al. (1998) Anal. Biochem. 70: 750-756). In a typical experiment, the target to be analyzed is expressed as described for FCS. The purified protein is then used in the assay without further preparation. It is bound to the SELDI chip either by utilizing the poly-histidine tag or by other interaction such as ion exchange or hydrophobic interaction. The chip thus prepared is then exposed to the potential ligand via, for example, a delivery system able to pipet the ligands in a sequential manner (autosampler). The chip is then submitted to washes of increasing stringency, for example a series of washes with buffer solutions containing an increasing ionic strength. After each wash, the bound material is analyzed by submitting the chip to SELDI-TOF. Ligands that specifically bind the target will be identified by the stringency of the wash needed to elute them.


Biacore relies on changes in the refractive index at the surface layer upon binding of a ligand to a protein immobilized on the layer. In this system, a collection of small ligands is injected sequentially in a 2-5 microlitre cell with the immobilized protein. Binding is detected by surface plasmon resonance (SPR) by recording laser light refracting from the surface. In general, the refractive index change for a given change of mass concentration at the surface layer is practically the same for all proteins and peptides, allowing a single method to be applicable for any protein (Liedberg et al. (1983) Sensors Actuators 4: 299-304; Malmquist (1993) Nature 361: 186-187). In a typical experiment, the target to be analyzed is expressed as described for FCS. The purified protein is then used in the assay without further preparation. It is bound to the Biacore chip either by utilizing the poly-histidine tag or by other interaction such as ion exchange or hydrophobic interaction. The chip thus prepared is then exposed to the potential ligand via the delivery system incorporated in the instruments sold by Biacore (Uppsala, Sweden) to pipet the ligands in a sequential manner (autosampler). The SPR signal on the chip is recorded and changes in the refractive index indicate an interaction between the immobilized target and the ligand. Analysis of the signal kinetics on rate and off rate allows the discrimination between non-specific and specific interaction.


The compounds that are active in the methods disclosed herein may be used to combat agricultural pests such as aphids, locusts, spider mites, and boll weavils as well as such insect pests which attack stored grains and against immature stages of insects living on plant tissue. The compounds are also useful as a nematodicide for the control of agriculturally important soil nematodes and plant parasites.


VI. Production of Peptides


Phage particles displaying diverse peptide libraries permits rapid library construction, affinity selection, amplification and selection of ligands directed against an essential protein (H. B. Lowman, Annu. Rev. Biophys. Biomol. Struct. 26, 401-424 (1997)). Structural analysis of these selectants can provide new information about ligand-target molecule interactions and then in the process also provide a novel molecule that can enable the development of new insecticides based upon these peptides as leads.


The invention will be further described by reference to the following detailed examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified.


EXAMPLES

Standard recombinant DNA and molecular cloning techniques used here are well known in the art and are described by Sambrook, et al., Molecular Cloning, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) and by T. J. Silhavy, M. L. Berman, and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1984) and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, pub. by Greene Publishing Assoc. and Wiley-Interscience (1987). Well known Drosophila molecular genetics techniques can be found, for example, in Robert, D. B., Drosophila, A Practical Approach (IRL Press, Washington, D.C., 1986).


Example 1
Identification of Lethal Lines

Essential nucleotide sequences are identified through the isolation of lethal mutants defective in development The genetic scheme for mobilization of P-lacW is as performed in Deak et. al, Genetics 147: 1697-1722 (1997). Additional lethal lines are identified and disclosed in Braun, A., B. Lemaitre, et al., Genetics 147: 623-634 (1997); Galloni, M. and B. A. Edgar, Development 126: 2365-2375 (1999); Gateff, E., Int. J. Dev. Biol. 38(4): 565-590 (1994); Mechler, B. M. J. Biosci., Bangalore 19(5): 537-556 (1994); Roch, F., F. Serras, et al., Mol. Gen. Genet. 257: 103-112 (1998); Russell, M. A., L. Ostafichuk, et al., Genome 41: 7-13 (1998); and in Torok, T., G. Tick et al. Genetics 135: 71-80 (1993), Schaefer et al., Aug. 8, 1999 Personal communication to FlyBase. Furthermore, the BDGP gene disruption project of single P-element insertions reveals lethal lines mutating 25% of vital Drosophila genes Spradling, A. C., D. Stern, et al., Genetics 153: 135-177 (1999).


Males carrying the transposase source P(Δ2-3) are crossed en masse to yellow white females homozygous for a P-lacW insertion on the X chromosome. Males carrying the PlacW insertion on the X and Δ2-3 on the third chromosome are collected from this cross. The F0 “jumpstart” males are crossed in groups of 10-15 to 20-25 females of w spl; Sb/TM3, Ser genetype. Male F1 progeny with pigmented eyes indicate that the P-lacW has jumped to an autosome. An average of 10-15 males from each F0 cross lacking Δ2-3 are crossed individually to y w, DTS4/TM3, Sb Ser females, that all third chromosomal insertions result in balanced F2 stocks. Insertions on other autosomes yield white-eyed flies in the F2 generation and are eliminated. The balanced third chromosome insertions are tested for lethality in the next generation by placing four to six pairs of y w; P-lacW/TM3, Sb Ser flies in a vial and examining their progeny for the presence of homozygous P-lacW flies. To analyze the lethal phase, the TM3, Sb Ser balancer is replaced by the TM6C, TB Sb chromosome. In such a genetic background, homozygous mutants can be identified by their wild-type body-length. An average of 10-15 pairs of flies are placed in vials supplemented with yeast paste, and the eggs are collected from each line for 1 day. The development of 50-100 progeny is monitored, and the presence of homozygotes are recorded in all developmental stages. Lethal phase is assigned to a developmental stage in which homozygote animals last appear. Lethal lines are identified and maintained.

TABLE 3P-element locationInverseseq IDp-element linePCRdf cross14l(1)G0335516M3h-f09Df(2L)Dwee[wo5]16l(3)064301979H5h-b01Previously verified18l(3)0924161022H5h-Previously verifiedc0320l(1)G0384449M3h-b09Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M522l(1)G0449267M3h-d07Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M524l(3)s1262151082H5h-GN50(63E; 64B)f0526l(1)G0435661m3hC(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+] na[+] Ste[+]28l(3)079101798H5h-e01df 084D04-06; 085B0632l(3)s1471041108H5h-6-7(82D; 82F)by62(85D; 85F)h0634l(3)047418957H5h-a05Previously verified36l(1)G0425619M5h-b-Dp(1; Y)619, y[+] B[S]/w[1] otd[9]/C(1)DX, y[1] w[1] f[1]e1038l(3)1224041079H5h-Previously verifiedf0240l(1)G0105360H5hADf(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]44l(3)057809971M5h-e06Previously Verified46l(1)G0127373M3h-f03Previously Verified48l(1)G0469629H3h-fC(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+] na[+] Ste[+]50l(3)S070103788M5h-h03091F01-02; 092D03-06 BL#301254l(3)S1041041057M5h-Previously Verifiedg0856l(3)s0906091017H5h-emc5(61C; 62A)a0358l(3)0939091026H5h-Previously Verifieda1160l(1)G0095354M3h-e10Df(1)GE202/Y; Dp(1; 2)sn[+]72d/Dp(?; 2)bw[D], bw[D]62l(1)G0031577M3h-h06BL3219 C(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+]na[+] Ste[+]64l(1)G0354524M3h-g04BL1319 Tp(1; 2)w-ec, ec[64d] cm[1] ct[6] sn[3]/C(1)DX, y[1] w[1] f[1]66l(1)G0062333H5h-b02Df(1)R20, y[1?]/C(1)DX, y[1] w[1] f[1]/Dp(1; Y)y[+]mal[+]74l(2)k00237AQ034169BL3219 C(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+]na[+] Ste[+]76l(1)G0181492H3h-fBL936 Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]78l(3)078514797H5h-d12def. 087D01-02; 088E05-0680l(3)s1121101069H5h-ry506(88B; 88D)e0482l(3)024120930H5h-e06Previously verified84l(1)G0150442M3h-b02Df(1)R20, y[1?]/C(1)DX, y[1] w[1] f[1]/Dp(1; Y)y[+]mal[+]88l(3)054211968H5h-a09Previously verified90l(1)G0399659m3hBL 901Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]92l(1)G0399659m3hBL 901Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]94l(3)S1040021061H5h-W4(75B; 75C)by62(85D; 85F)d0896l(3)S1337051092M5h-Previously verifiedf0998l(3)041706949H5h-g10Previously verified100l(1)G0251392M3h-f11Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]102l(3)1004091050H5h-crb87-5(95F; 96A)c09104l(1)G0491643M5h-b-BL3219 C(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+]g11na[+] Ste[+]108l(1)G0306603m3hBL1879 Df(1)GE202/Y; Dp(1; 2)sn[+]72d/Dp(?; 2)bw[D], bw[D]112l(1)G0344609H5hABL3219 C(1; Y)1, Df(1)g, y[1] f[1] B[1]/C(1)A, y[1]/Dp(1; f)LJ9, y[+] g[+]na[+] Ste[+]116l(3)s0837051006H5h-2-2(81F; 82F)h07118l(1)G0044319M3h-c02Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]120l(1)G0012300M5h-b-Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]e08122l(1)G0012300M5h-b-Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]e08124l(1)G0431566H3h-fBL 901 Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]126l(1)G0130376H3h-f-Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]e10128l(1)G0010576M3h-c07BL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5130l(3)s1186021076H5h-ZP1(66A; 66C)G28(66B; 66C)ry506(88B; 88D)red1(88B; 88D)e11132l(1)G0285508H3h-f-BL3033 Df(1)R20, y[1?]/C(1)DX, y[1] w[1] f[1]/Dp(1; Y)y[+]mal[+]e03134l(3)s1372121094H5h-GN50(63E; 64B)g05136P{GawB}c338F49 (13m3h138l(1)G0334515M3h-g09BL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5140l(1)G0464627M3h-dBL5292 (008C-D; 009B + 001A01; 001B02)142l(3)0990131044H5h-Previously Verifiedc04144l(3)1449121103H5h-Previously verifiedh01146l(1)G0345471M3h-d03BL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5148l(1)G0453663M3h-d03BL5292 y[1] nej[Q7] v[1] f[1]/Dp(1; Y)FF1, y[+]/C(1)DX, y[1] w[1] f[1]150l(1)G038616H5hBBL 929 Df(1)v-L15, y[1]/C(1)DX, y[1] w[1] f[1]; Dp(1; 2)v[+]75d/+152l(1)G0492666M3h-d06Previously verified154l(1)G0052325M5h-b-Df(1)v-N48, f[*]/Dp(1; Y)y[+]v[+]#3/C(1)DX, y[1] f[1]f01156l(1)G0269653M5h-bBL3033 Df(1)R20, y[1?]/C(1)DX, y[1] w[1] f[1]/Dp(1; Y)y[+]mal[+]158l(1)G0241422H3h-f-Dp(1; Y)BSC1, y[+]/w[67c23] P{lacW]l(1)G0060[G0060]/C(1)RM, y[1] v[1]d02162l(1)G0141277M5h-b-Dp(1; Y)BSC1, y[+]/w[67c23] P{lacW]l(1)G0060[G0060]/C(1)RM, y[1] v[1]b08164l(1)G0250468H5h-e02BL5292 y[1] nej[Q7] v[1] f[1]/Dp(1; Y)FF1, y[+]/C(1)DX, y[1] w[1] f[1]166l(3)sS030003943H5h-e09M-Kx1(86C; 87B)T-61(86E; 87A)T32(86E; 87C)168l(1)G0428456M3h-c04BL1538 Df(1)os[UE69]/C(1)DX, y[1] f[1]/Dp(1; Y)W39, y[+] ! = fcl[+]Y170l(3)072603996H5h-h02previously verified172l(3)S0943101029H5h-previously verifiedc08174l(1)G0220467M3h-d02M19 BL1527 Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX,y[1] f[1]176l(3)090417811H5h-e11def. 087D01-02; 088E05-06178l(3)s2172AQ034107gasfilling screen180l(1)G0025310M3h-d09Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5182l(1)G0076343M34-d11Previously verified184l(1)G0151482M3h-g04BL1527 Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]186l(3)S069605990M5h-f06previously verified188l(1)G0221434H3h-f-Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y)shi[+]3, y[+]f02190l(1)G0075342M3h-d12Df(1)v-N48, f[*]/DP(1; Y)y[+]#3/C(1)DX, y[1] f[1]192l(3)s002001886H5h-c09R-G5(62A; 62D)R-G7(62B; 62F)196l(1)G0046321M3h-c04Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]198l(1)G0020303M5h-b-Dp(1; Y)619, y[+] B[S]/w[1] otd[9]/C(1)DX, y[1] w[1]f[1]f06200l(3)s0952141032H5h-faf-BP(100D; 100F)b05202l(1)G0481275H5bBDp(1; Y)619, y[+] B[S]/w[1] otd[9]/C(1)DX, y[1] w[1] f[1]206l(3)s1196081077H5h-B81(99C; 100F)e12208l(1)G0172650H3h-f-BL5292 y[1] nej[Q7] v[1] f[1]/DP(1; Y)FF1, y[+]/C(1)DX, y[1] w[1] f[1]c12210l(1)G0429564M3h-b11BL5459 C(1; Y)6, y[1] w[*] P{white-un4}BE1305 mew[023]/C(1)RM, Y[1]pn[1] v[1]; Dp(1; f)y[+]212l(3)005028892H5h-a04Previously verified216l(1)G0343520M5h-bBL5594 Df(1)dhd81, w[1118]/C(1)DX, y[1] f[1]; Dp(1; 2)4FRDup/+218l(1)G0343520M5h-bBL5594 Df(1)dhd81, w[1118]/C(1)DX, y[1] f[1]; Dp(1; 2)4FRDup/+220l(1)G0174463M3h-c10Df(1)dhd81, w[1118]/C(1)DX, y[1] f[1]; Dp(1; 2)4FRDup/+224l(1)G0132377H3h-f-Df(1)svr, N[spl-1] ras[2] fw[1]/DP(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]f10226l(1)G0144387M3h-f06Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]228l(1)G0144387M3h-f06Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]230l(1)G0312291M5h-b-Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]g08232l(3)S044402954M5h-b06Previously Verified234l(1)G0375534M5h-b-BL936 Df(1)64c18, g[1] sd[1]/Dp(1; 2; Y)w[+]/C(1)DX, y[1] w[1] f[1]h03236l(1)G0159486M3h-d09BL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5238l(1)G0227651H3h-fBL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5240l(1)G0212433M3h-a06Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y)shi[+]3, y[+]242l(1)G0296383H5hADf(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1]0 f[1]244l(3)j2B9AQ026304gasfilling screen248l(1)G0007298M3h-a08Previously verified250l(3)070006991H5h-b08Previously verified252l(1)G0423454M3h-c02Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]254l(1)G0361527H3h-fBL556 Dp(1; Y)BSC1, y[+]/w[67c23] P{lacW]l(1)G0060[G0060]/C(1)RM,y[1] v[1]256l(1)G0290285H5hADf(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5258l(1)G0436570M3h-c03BL 929 Df(1)v-L15, y[1]/C(1)DX, y[1] w[1] f[1]; Dp(1; 2)v[+]75d/+260l(1)G0111362M5hADp(1; Y)BSC1, y[+]/w[67c23] P{lacW]1(1)G0060[G0060]/C(1)RM, y[1] v[1]262l(1)G0183264H3h-f-Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]e07264l(3)S1002091049H5h-Previously verifiedd08266l(3)S1002091049H5h-Previously verifiedd08268l(1)G0438572M3h-c05BL5270 Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y)shi[+]3, y[+]270l(1)G0116366M5h-b-Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y) shi[+]3, y[+]f09272l(3)S025007934M5h-g05Previously verified274l(1)G0419561M3h-b09BL 929 Df(1)v-L15, y[1]/C(1)DX, y[1] w[1] f[1]; Dp(1; 2)v[+]75d/+276l(3)S008418900H5h-a05Previously verified278l(3)1411101098H5h-Previously verifiedg08280l(3)S1480111110H5h-P115(89B; 89E)C4(89E; 90A)g08282l(3)S023204923M5h-f05Previously verified284l(3)S0964041037H5h-Previously verifieda08286l(3)1455111104H5h-Previously verifiedh02292l(3)S1100131066H5h-Previously verifiedh08294l(3)010605904H5h-d11Previously verified296l(3)1006041051H5h-Previously verifiedc10302l(3)001604883H5h-c06Previously verified304l(1)G0358526M3h-g06BL1538 Df(1)os[UE69]/C(1)DX, y[1] f[1]/Dp(1; Y)W39, y[+] ! = fcl[+]Y306l(3)067006984H5h-g07Previously Verified308l(1)G0070338M3h-d08Df(1)os[UE69]/C(1)DX, y[1] f[1]/Dp(1; Y)W39, y[+] ! = fcl[+]Y310l(3)02240G00700Df(3L)AC1312l(3)0882051013H5h-Previously Verifiedc01314l(3)S042228951H5h-f01vin2(67F; 68D)vin5(68A; 69A)316l(3)S050407964H5h-a07M-Kx1(86C; 87B)T-61(86E; 87A)T32(86E; 87C)318l(3)011046908H5h-d09Previously verified320l(3)S0942041028H5h-ea(88E; 89A)b01322l(3)001917738H5h-a03def. 089E01-F04; 091B01-B02324l(3)131602858H5h-h10def. 089E01-F04; 091B01-B02326l(1)G0451624M3h-a10BL 901 Df(1)svr, N[spl-1] ras[2] fw[1]/Dp(1; Y)y[2]67g19.1/C(1)DX, y[1] f[1]328l(3)S022231920H5h-g04Previously verified330l(3)S085401225M3dDf(3L-Xs-533/TM6B Sb[1]Ser[1] (76B4-77B)332l(3)075515794H5h-d09def. 076B04; 077B334l(3)131602858H5h-h10def. 089E01-F04; 091B01-B02336l(3)058302972H5h-a11Previously verified338l(3)058302972H5h-a11Previously verified340l(3)S005916895H5h-d01lxd6(67F; 68D)P14(90C; 91A)342l(3)025616752H5h-b02def. 087D01-02; 088E05-06348l(3)S0893021014H5h-AC1(67A; 67D)a01354l(2)06444AQ025653In(2R)vg[W]356l(3)026115938H5h-e07Previousyl verified358l(1)G0461626M3h-a12BL5279 Df(1)JC70/Dp(1; Y)dx[+]5, y[+]/C(1)M5360l(2)04329G00564Df(2R)vg135 Df(2R)CX1362l(3)1131051070H5h-Previously verifiede05364l(1)G0213495M5h-bBL1537 Dp(1; Y)W73, y[31d] B[1], f[+], B[S]/C(1)DX, y[1] f[1]/y[1]baz[EH171]366l(3)003606888H5h-d06Previously verified368l(3)S005042893H5h-c01eN19(93B; 94)eR1(93B; 93D)372l(3)S0751011002H5h-pXT103(85A; 85C)h04374l(1)G0455269H5h-a01BL5678 duplication376l(1)G0260432M3h-a05Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y)shi[+]3, y[+]378l(3)S086909806H5h-b04087D01-02; 088E05-06 BL1534380l(1)G0272435H3h-f-M26 BL5270 Df(1)19, f[1]/C(1)RM, y[1] shi[1] f[1]; Dp(1; Y)shi[+]3, y[+]g02


Example 2
Sequence Determination

Inverse PCR: To determine the flanking sequence of the lethal lines, the “Inverse PCR and Cycle Sequencing Protocol for Recovery of Sequences Flanking PZ, PlacW; and PEP elements” of E. Jay Rehm, Berkeley Drosophila Genome Project on the world wide web at fruitfly.org/methods/ is used with slight modifications. These modifications include the following: genomic DNA is obtained from 10 flies, rather than 30 flies, with adjustments for final concentrations; all DNA precipitations are performed using glycogen; for some reactions, the digest volume is used in the appropriate ligations; the number of cycles in PCR reactions was increased to 40; Pry1 and Pry2 were used to sequence the PEP line flanking sequences.


Genomic DNA isolation: Flies are collected and frozen at −20° C. until ready for use. Genomic DNA is prepared by grinding flies in 200 μl Buffer A with a disposable grinder 30× (Buffer A is composed of 100 mM Tris-Cl, pH7.5, 100 mM EDTA, 100 mM NaCl, 0.5% SDS). Add 200 μl additional Buffer A; grind another 15×. Keep on ice until finished. Incubate at 65° C. for 30 minutes. Vortex to mix. Add 800 μl freshly made LiCl/KAc Solution (LiCl/Kac Solution is comprised of 1 part 5 M KAc and 2.5 parts 6 M LiCl). Vortex. Incubate −20° C. for 20 minutes. Spin at maximum speed at room temperature 15+ minutes. Transfer 1 ml supernatant to a clean tube avoiding floating debris. Add 600 μl room temperature isopropanol to supernatant. Mix well by tipping. Add 0.5 μl glycogen. Vortex. Incubate at room temperature for 5 minutes. Spin 15 minutes at room temperature, maximum speed. Aspirate away the supernatant Wash 2× with 500 μl 70% room temperature ethanol; vortex between washes. Spin for 10 minutes at room temperature, maximum speed. Aspirate away supernatant. Dry in a speed vacuum for 10 minutes. Resuspend in 50 μl TE+0.1 mg/ml RNAse A {for 1 ml TE/RNAse A Solution, add 990 μl TE+10 μl RNAse A (10 mg/ml)). Check 5 μl on 0.8% gel.


Digest Genomic DNA (Sau3A I, HinP1I, or Msp I—done separately): Set up digests in 96 well tray. Per reaction, add 10 μl genomic DNA, 5 μl 10× Buffer, 2 μl 0.1 mg/ml RNAase A stock, 30.5 μl dH2O, 10 units of enzyme (8 units for Sau 3AI), 0.5 μl of 100×BSA (for Sau 3AI only). Incubate at 37° C. for 2.5 hours. Check on 0.8% gel before heat-inactivating at 65° C. for 20 minutes.


Ligate P Element and Flanking DNA: Set-up ligation tube with 400 μl of ligation mixture then add 30-50 μl of the digest: Per reaction, add 30 μl of digested genomic DNA, 43 μl of 10× ligation buffer (NEB), 375 μl of dH2O, and 2 μl of ligase (2 Weiss units). Incubate overnight at 4° C. Total reaction volume is adjusted as appropriate.


Precipitate Ligated DNA: To ligation tube, add 40 μl 3M NaAc pH5.2+1 ml 100% room temperature ethanol+1 μl glycogen. Mix by tipping. Incubate −20° C. for 15+ minutes. Spin 15 minutes, 4° C. Aspirate away supernatant Wash with 500 μl room temperature 70% ethanol. Vortex. Spin room at temperature for 10 minutes. Aspirate away supernatant. Dry in speed vacuum for 10 minutes. Resuspend in 50μl TE. Vortex to mix. Transfer to 96 well plate.


PCR: Set up PCR reactions in 96 well plates (Applied Biosystems). Set up PCR reactions with primers appropriate for the type of P element and the end of the element from which genomic sequence is to be recovered.


Primers for PCR: (type of P element 5′ or 3′ end forward primer reverse primer annealing temperature):

PZ P-element5′ endPlac4Plac160°PZ P-element3′ endPry4Pry155°PZ P-element3′ endPry2Pry160°PlacW P-element5′ endPlac4Plac160°PlacW P-element3′ endPry4Plw3-155°PlacW P-element3′ endPry2Pry160°PEP P-element5′ endPwht1Plac160°PEP P-element3′ endPry4Pry155°PEP P-element3′ endPry2Pry160°


The Pry2/Pry1 combination has a higher annealing temperature than the Pry4/Pry1 and Pry4/Plw3-1 combinations, but the resulting PCR products do not allow sequencing directly off the 3′ end of the P-element. The latter primer combinations are therefore used in all initial experiments; the Pry2/Pry1 combination can be used in those cases where strong and unique bands do not result.


Per reaction: 10 μl of ligated genomic DNA, 1 μl of 10 mM dNT mix, 1 μl of 10 μM forward primer stock, 1 μl of 10 μl reverse primer stock, 5 μl of 10× Qiagen Taq buffer, 31.5 μl of dH2O, 0.5 μl of Qiagen Taq.


Cycles: 1×95° C. for 5 minutes; 40×(95° C. for 30 seconds; 60° C. (high temp) or 55° C. (low temp) for 30 seconds; 68° C. for 2 minutes); 1×72° C. for 10 minutes; hold at 4° C.; run 10 μl on 1.5% gel to check. Rearray positive wells to 96 well plate for sequencing clean-up. The primer sets for PCR are as shown in the table below:

TABLE 4PCR PrimersDigest, End, TemperatureForward PCR PrimerReverse PCR PrimerH5hPlac4Plac1H3hPry2Pry1H3lPry4Plw3-1M5hPlac4Plac1M3hPry2Pry1M3lPry4Plw3-1S5hPlac4Plac1S3hPry2Pry1S3lPry4Plw3-1


PCR Primer Sequences (5′ to 3′):

Plac4 (27)-act gtg cgt tag gtc ctg ttc att gttSEQ ID NO:1Plac1 (24)-cac cca agg ctc tgc tcc cac aatSEQ ID NO:2Pry4 (23)-caa tca tat cgc tgt ctc act caSEQ ID NO:3Pry1 (26)-cct tag cat gtc cgt ggg gtt tga atSEQ ID NO:4Pry2 (28)-ctt gcc gac ggg acc acc tta tgt tat tSEQ ID NO:5Plw3-1 (19)-tgt cgg cgt cat caa ctc cSEQ ID NO:6Pwht1 (19)-gta acg cta atc act ccg aac agg tca caSEQ ID NO:7


Enzymatic Clean-Up for Sequencing: To 40 μl PCR reaction, add 4 μl of enzyme mix. Incubate at 37° C. for 1 hour. Inactivate at 70° C. for 10 minutes. (Enzyme Mix consists of 2.5 U/μl Exonuclease I (Amersham E700732), 0.5 U/μl Shrimp Alkaline Phosphatase (Amersham E70183), 1× Amplitaq PCR buffer, add dH2O to final volume.)


Example 3
Sequence Analysis

Sequence of the flanking sequence generated by inverse PCR is performed on an ABI 3700 sequencer (Perkin Elmer) using BIG DYE sequencing reaction.


Primer sets for sequencing are as shown in the table below:

TABLE 5PCR Primers for Flanking SequencesDigest, End, TemperatureForward PrimerReverse PrimerH5hSplac2Sp1H3hPry2Sp5H3lSpep1Sp5M5hSplac2Sp1M3hPry2Sp5M3lSpep1Sp5S5hSplac2Sp1S3hPry2Sp6S3lSpep1Sp6


The following primer sets are designed to sequence both ends of PCR products recovered from PlacW and PZ strains:


Splac2 and Sp1—for use with the Plac4/Plac1 5′ PCR primer combination with either PZ or PlacW P-elements; allows sequencing of both ends of the PCR fragment.


Spep1 and Sp3—for use with the Pry4/Pry1 3′ PCR primer combination with PZ P-elements; allows sequencing of both ends of the PCR fragment.


Spep1 and Sp6—for use with the Pry4/Plw3-1 3′ PCR primer combination with PlacW P-elements where Sau3a digestion is performed; allows sequencing of both ends of the PCR fragment.


Spep1 and Sp5—for use with the Pry4/Plw3-1 3′ PCR primer combination where HinP1 digestion is performed; allows sequencing of both ends of the PCR fragment.


Pry1 and Pry2—for use with the Pry1/Pry2 3′ PCR primer combination; allows sequencing of both ends of the PCR fragment.


The PCR products recovered from PEP strains are sequenced with the following primers: Sp1—for use with the Pwht1/Plac1 5′ PCR primer combination with the PEP element; Spep1—for use with the Pry4/Pry1 3′ PCR primer combination with the PEP element; Pry1 and Pry2 for use with the Pry1/Pry2 3′ PCR primer combination with the PEP element.


Primer Sequences (5′ to 3′):

Splac2 (25)-gaa ttc act ggc cgt cgt ttt aca aSEQ ID NO:8Sp1 (22)-aca caa cct ttc ctc tca aca aSEQ ID NO:9Sp3 (24)-gag tac gca aag ctt taa cta tgtSEQ ID NO:10Sp6 (23)-tga cca cat cca aac atc ctc ttSEQ ID NO:11Sp5 (25)-gca tca caa aaa tcg acg ctc aag tSEQ ID NO:12Spep1 (19)-gac act cag aat act att cSEQ ID NO:13


Melting temperatures of sequencing primers:

    • Splac2—60.1° C.
    • Sp1—50.6° C.
    • Sp3—49.3° C.
    • Sp6—54.9° C.
    • Sp5—60.3° C.
    • Spep1—44.8° C.


Example 4
Secondary Confirmation of Lethality

The lethality of the chromosome carrying the P-element insertion is demonstrated genetically as described in Example 1. The essential Drosophila nucleotide sequences are identified by isolating nucleotide sequences flanking the P-element insertion and aligning those sequences with genomic Drosophila sequence obtained from the Celera Drosophila database. However, in some instances, a second site mutation exists on the chromosome that is responsible for the lethality. In other instances, the location of the flanking sequence is such that determination of which gene(s) are affected by the P-element insertion is rendered difficult or impossible. Thus, to provide secondary confirmation that the gene indicated is essential, there are many methods that one skilled in the art can use, e.g., rescue of the lethality using transformation technology, perturbation of the gene in a targeted manner, or failure to complement a deficiency.


To provide secondary confirmation, lethal lines are crossed to a line containing a deficiency. This creates a hemizygous condition in that particular region and reveals the recessive phenotype of the P-element. Complementation with deficiencies that unequivocally remove the P-element insertion site is taken as proof that the P-element does not cause the associated phenotype. Failure to complement indicates that the strain is verified. This method is as performed in Spradling, A. C., D. Stern, et al., Genetics 153: 135-177 (1999). If the insert is present on the X chromosome, which is present in two copies in females but only one copy in males, then the recessive phenotype of the P-element insert is revealed by this hemizygous condition in males. A rescue cross is performed to a stock containing a duplication spanning the region of the insert on the X chromosome on one of the autosomes. If the males survive then the presence of an essential gene disrupted by the P-element but rescued by the duplication is confirmed. While lines with secondary mutations closely linked to the P insertion might be erroneously verified by these procedures, further molecular and genetic analyses suggest that the frequency of such errors is small. RNA interference, described in Fire, A., S. Xu, et al., Nature 391, 806-811 (1998) and Kennerdell, J. R. and Carthew, R. W., Cell 95, 1017-1026 (1998), is used as a method to target a gene of interest and demonstrate that the perturbation of the identified gene produces a lethal phenotype.


Example 4
Double-Stranded RNA Interference

Preparation of dsRNA for Injection. Sequences to be expressed as dsRNA were cloned into Bluescript KS(+) (Stratagene of La Jolla, Calif.), linearized with the appropriate restriction enzymes, and transcribed in vitro with the Ambion T3 and T7 Megascript kits following the manufacturer's instructions (Ambion Inc. of Austin, Tex.). Transcripts were annealed in injection buffer (0.1 mM NaPO4 pH 7.8, 5mM KCl) after heating to 85° C. and cooling to room temperature over a 1- to 24 hr period. All annealed transcripts were analyzed on agarose gels with DNA markers to confirm the size of the annealed RNA and quantitated as described previously (Fire et al. (1998) Nature 391(6669):806-811). Injected RNA was not gel-purified. Injection of 0.1 nl of a 0.1- to 1.0-mg/ml solution of a 1-kb dsRNA corresponds to roughly 107 molecules/injection.


Injection of Drosophila melanogaster Embryos. Fly cages were set up using 2- to 4day flies. Agar-grape juice plates were replaced every hour to synchronize the egg collection for 1-2 days. The eggs were collected over a 30-to 60-min period for subsequent injection. The eggs were washed into a nylon mesh basket with tap water. The chorion was removed by brief soaking in a dilute bleach solution. Eggs were positioned on a glass slide such that each egg was in a same orientation. Double-stranded RNA was injected into middle of each egg using an Eppendorf transjector (Eppendorf Scientific, Inc. of Westbury, N.Y.). Following injection, slides were stored in a moist chamber to prevent dessication of the embryos. Embryos were monitored for development and transferred as first intar larvae to vials containing Drosophila medium. Methods for rearing Drosophila staging and common genetic techniques can be found, for example, in Roberts (1986) Drosophila melanogaster, A Practical Approach, IRL Press, Washington, D.C.; Ashburner (1989a) Drosophila: A Laboratory Handbook, Cold Spring Harbor Laboratory Press, New York, N.Y.; Ashburner (1989b) Drosophila: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, N.Y.; Goldstein & Fyrberg, eds (1994) in Methods in Cell Biology. Vol. 44, Academic Press, San Diego, Calif.


The data in Table 6 demonstrates the lethal effect of disrupting the production of protein from the message of the specified gene through RNAi. Based on data from postitve and negative controls, a reduction in survival (% viable adults from developed eggs) below 38% represents a significant lethal effect. Many genes show a complete loss of survivability (with 0% viable). Others show a range of phenotypic penetrance, which is most likely due to the variability of the RNAi technique, but are still considered lethals because they are significantly below controls.

TABLE 6Data for dsRNA Interference# eggs% viableshowingadults fromInventor's# eggsmorphological# hatcheddevelopedseq IDreferenceInjecteddevelopmentlarvae# pupae# adultseggsnone, buffer only94180658050043353.7214GIN00231, CT28483163148107282617.5730GIN00961, CT31117472386170810.2642GIN01243, CT362411079981977.0752GIN01682, CT146514012787231511.8168GIN01885, CT13424170154781785.1970GIN01896, CT1493216414078443827.1472GIN01977, CT23511797018171521.4386GIN02340, CT289311901590000.00106GIN03775, CT3381917214816000.00110GIN03797, CT3384113612712000.00114GIN04053, CT3509168145106110.69160GIN05757, CT4810159144109373222.22194GIN07111, CT600715914094000.00204GIN07278, CT67381741667310.60214GIN07446, CT90211251191000.00222GIN07609, CT6171372316119000.00246GIN08205, CT1251771756943326254.39274GIN08858, CT1487417716113331.86288GIN09788, CT179381008371522.41290GIN09819, CT17971181142107710.70298GIN10338, CT1978817013788510.73300GIN10364, CT1985058554714610.91344GIN11831, CT24122103870000.00346GIN11918, CT243464694083012578821.57350GIN11993, CT2443714513093000.00352GIN12074, CT182571049380333.23354GIN12174, CT24731168145122110.69360GIN12437, CT252744734243342376314.86370GIN13270, CT275431019278222.17


Example 5
Isolation of Full Length cDNA

A cDNA screen is performed using a Drosophila melanogaster cDNA library probed with a portion of each nucleotide sequence disclosed in the Sequence Listing. Positive colonies are selected, a subset sequenced, and a clone corresponding to the full-length cDNA is recovered. Alternatively, primers from the predicted 5′ and 3′ end are used in polymerase chain reaction with either a Drosophila cDNA library or first strand cDNAs obtained by reverse transcription of Drosophila mRNAs as template to amplify a fragment representing the full-length clone.


Example 6
Expression of Recombinant Protein in Insect Cells

Baculovirus vectors, which are derived from the genome of AcNPV virus, are designed to provide high levels of expression of cDNA in the SF9 line of insect cells (ATCC CRL#1711). Recombinant baculovirus expressing the cDNA of the present invention is produced by the following standard methods (InVitrogen MaxBac Manual): cDNA constructs are ligated into the polyhedrin gene in a variety of baclovirus transfer vectors, including the pAC360 and the BleAc vector (InVitrogen). Recombinant baculoviruses are generated by homologous recombination following co-transfection of the baculovirus transfer vector and linearized AcNPV genomic DNA (Kitts, P. A., Nucleic Acid Res. 18: 5667 (1990)) into SF9 cells. Recombinant pAC360 viruses are identified by the absence of inclusion bodies in infected cells and recombinant pBlueBac viruses are identified on the basis of B-galactosidase expression (Summers, M. D. and Smith, G. E., Texas Agriculture Exp. Station Bulletin No. 1555). Following plaque purification, the Drosophila cDNA expression is measured.


The cDNA encoding the entire open reading frame for the Drosophila cDNA is inserted into the BamHI site of pBlueBacII. Constucts in the positive orientation, which are identified by sequence analysis, are used to transfect SF9 cells in the presence of linear AcNPV wild type DNA. Authentic, active Drosophila cDNA is found in the cytoplasm of infected cells. Active Drosophila cDNA is extracted from infected cells by hypotonic or detergent lysis.


Example 7
Expression of Recombinant Protein in E. coli

A cDNA clone of the present invention is subcloned into an appropriate expression vector and transformed into E. coli using the manufacturer's conditions. Specific examples include plasmids such as pBluescript (Stratagene, La Jolla, Calif.), pFLAG (International Biotechnologies, Inc., New Haven, Conn.), and pTrcHis (Invitrogen, La Jolla, Calif.). E. coli is cultured, and expression of the recombinant protein is confirmed. Recombinant protein is then isolated using standard techniques.


Example 8
In Vitro Binding Assays

Recombinant protein is obtained, for example according to Example 6 or Example 7. The protein is immobilized on chips appropriate for ligand binding assays. The protein immobilized on the chip is exposed to sample compound in solution according to methods well know in the art. While the sample compound is in contact with the immobilized protein measurements capable of detecting protein-ligand interactions are conducted. Examples of such measurements are SEDLI, biacore and FCS, described above. Compounds found to bind the protein are readily discovered in this fashion and are subjected to further characterization.


The above disclosed embodiments are illustrative. This disclosure of the invention will place one skilled in the art in possession of many variations of the invention. All such obvious and foreseeable variations are intended to be encompassed by the appended claims.


The numerous publications and patents referred to in this document are hereby incorporated by reference, in their entirety.

Claims
  • 1. A method for identifying a compound that inhibits the activity of a protein essential for Drosophila viability, comprising: (a) expressing in a recombinant host a DNA molecule comprising (i) a nucleotide sequence selected from the group consisting of the even numbered SEQ ID NOs:14-380, or (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of the odd numbered SEQ ID NOs:15-381, to produce a protein essential for Drosophila viability; (b) testing compounds suspected of having the ability to inhibit the activity of the protein expressed in (a); and (c) identifying a compound tested in (b) that inhibits the activity of the protein.
  • 2. A method for killing or inhibiting the growth or viability of an insect, comprising applying to the insect a compound identified according to the method of claim 1.
  • 3. A method for identifying a compound that interacts with a protein essential for Drosophila viability, comprising: (a) expressing in a recombinant host a DNA molecule comprising (i) a nucleotide sequence selected from the group consisting of the even numbered SEQ ID NOs:14-380, or (ii) a nucleotide sequence encoding an amino acid sequence selected from the group consisting of the odd numbered SEQ ID NOs:15-381, to produce a protein essential for Drosophila viability; (b) testing compounds suspected of having the ability to interact with the protein expressed in (a); and (c) identifying a compound tested in (b) that interacts with the protein.
  • 4. A method for killing or inhibiting the growth or viability of an insect, comprising applying to the insect a compound identified according to the method of claim 3.
  • 5. A method for killing or inhibiting the growth or viability of an insect, comprising inhibiting expression in said insect of a protein having at least 60% sequence identity to an amino acid sequence selected from the group consisting of the odd numbered SEQ ID NOs:15-381.
  • 6. The method of claim 5, wherein expression of said protein is inhibited by disruption in said insect of a nucleotide sequence having at least 60% sequence identity to a nucleotide sequence selected from the group consisting of the even numbered SEQ ID NOs:14-380.
  • 7. The method of claim 6, wherein said nucleotide sequence is disrupted by RNA interference.
Parent Case Info

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/422,377 filed Oct. 30, 2002, which is incorporated by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US03/24982 8/8/2003 WO 3/14/2005
Provisional Applications (1)
Number Date Country
60422377 Oct 2002 US